
==== Front
J Nanobiotechnology
J Nanobiotechnology
Journal of Nanobiotechnology
1477-3155
BioMed Central London

38926780
2580
10.1186/s12951-024-02580-8
Review
Advanced gene nanocarriers/scaffolds in nonviral-mediated delivery system for tissue regeneration and repair
Zhang Wanheng 13
Hou Yan 12
Yin Shiyi 3
Miao Qi 3
Lee Kyubae 4
Zhou Xiaojian zhouxiaojian504@hotmail.com

5
Wang Yongtao yongtao_wang@shu.edu.cn

12
1 https://ror.org/006teas31 grid.39436.3b 0000 0001 2323 5732 Institute of Geriatrics, School of Medicine, Affiliated Nantong Hospital of Shanghai University (The Sixth People’s Hospital of Nantong), Shanghai University, Shanghai, 200444 China
2 https://ror.org/006teas31 grid.39436.3b 0000 0001 2323 5732 Joint International Research Laboratory of Biomaterials and Biotechnology in Organ Repair (Ministry of Education), Shanghai University, Shanghai, 200444 China
3 https://ror.org/01sfm2718 grid.254147.1 0000 0000 9776 7793 Department of Pharmacy, China Pharmaceutical University, Nanjing, 210009 China
4 https://ror.org/02v8yp068 grid.411143.2 0000 0000 8674 9741 Department of Biomedical Materials, Konyang University, Daejeon, 35365 Republic of Korea
5 grid.16821.3c 0000 0004 0368 8293 Department of Pediatrics, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200080 China
26 6 2024
26 6 2024
2024
22 3769 3 2024
24 5 2024
© The Author(s) 2024, corrected publication (2024)
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Tissue regeneration technology has been rapidly developed and widely applied in tissue engineering and repair. Compared with traditional approaches like surgical treatment, the rising gene therapy is able to have a durable effect on tissue regeneration, such as impaired bone regeneration, articular cartilage repair and cancer-resected tissue repair. Gene therapy can also facilitate the production of in situ therapeutic factors, thus minimizing the diffusion or loss of gene complexes and enabling spatiotemporally controlled release of gene products for tissue regeneration. Among different gene delivery vectors and supportive gene-activated matrices, advanced gene/drug nanocarriers attract exceptional attraction due to their tunable physiochemical properties, as well as excellent adaptive performance in gene therapy for tissue regeneration, such as bone, cartilage, blood vessel, nerve and cancer-resected tissue repair. This paper reviews the recent advances on nonviral-mediated gene delivery systems with an emphasis on the important role of advanced nanocarriers in gene therapy and tissue regeneration.

Keywords

Advanced gene/Drug nanocarriers
Nonviral-mediated delivery system
Gene therapy
Tissue regeneration
Cancer-resected tissue repair
National Natural Science Foundation of China82302401 Shanghai Overseas High-Level Talent Project and High-End Foreign Experts Introduction PlanG2023013020L issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Tissue defects including wound, infection and tumor removal have become a great challenge in clinic around the world [1–3]. Due to poor intrinsic repair capacity in somatic cells and differentiated cells, a myriad of tissues and organs are urgently desired for in vivo clinical transplantation to repair damaged tissues, organs and parts in recent years [4]. Therefore, tissue regeneration technology has been rapidly developed and widely applied in tissue engineering since it is firstly proposed by American National Science Foundation (NSF) in 1988 [5]. Tissue engineering is also defined to apply the basic criterion and manner of engineering science and life science to understand the structure-and-function relationship between physiological or pathological tissues and organs, and further develop artificial substitutes with biological activity to restore, maintain and improve the functions of tissues and organs [6]. Current strategies that are curative and work well consisting of autologous transplantation, allograft transplantation and artificial substitutes for tissue regeneration [7]. However, these methods suffer from some inevitable drawbacks, such as donor shortage and immune rejection response and so on [6, 8]. To circumambulate these problems, tremendous efforts have been contributed to explore novel tissue regeneration techniques with efficient repair ability and low immunogenicity [9, 10].

Gene therapy has provided a potential tactic to aid in the tissue regeneration and repair for destructive tissues [11, 12]. In this process, exogenous genes are delivered into targeting damage sites by gene carriers to achieve effective gene therapy of tissues and organs [13]. Generally, gene delivery carriers can be divided into viral and nonviral-mediated vectors [14]. Viral vectors can incorporate exogenous genes into DNA sequence of host cells to form stable transfection, consisting of genetic materials (RNA or DNA), protein-coated capsid and envelope of lipids surrounding the capsid [15]. Viral vectors with the advantages of stability, high transfection efficiency and extended expression window of related genes have been used in many clinical trials for cancer therapy, cardiovascular disease treatment and tissue regeneration [16–20]. Currently, the most commonly used viral vectors include retrovirus (RV), lentivirus (LV), adeno-associated virus (AAV), and adenovirus (AV) for gene delivery and therapy [21, 22]. Although viral-based gene delivery vector has gained a huge success in transfection efficiency and stability, the off-target effect, immune related adverse risk and restricted viral tropism are still inevitable events, which limit the further clinical application and development especially for AAV vectors [23–25]. These challenges motivate researchers to explore the alternative carriers to realize precise gene delivery. Advanced functional biomaterial-based gene delivery systems open a new insight for gene therapy by the means of encapsulation and immobilization of nonviral carriers [15]. Biomaterials-based gene delivery has attracted more and more attention in tissue regeneration and repair, due to their economic cost, low immunogenicity and more accurate local delivery ability [26]. Advanced biomaterials, including inorganic materials, polymer materials, lipids, proteins and peptides, exosomes and DNA nanostructures for gene therapy mainly have the characteristics of good biocompatibility, targeting accuracy ability and excellent degradability [27, 28]. Further, advanced biomaterials-based gene carriers have also been investigated and applied in tissue regeneration, such as bone, cartilage, blood vessel, nerve and cancer therapy [29–34]. Different tissue engineering application aspects with their specific features are matched with various nonviral biomaterials [35]. The biological outcome of gene delivery and therapy depends heavily on the selection of gene vectors. Better biomaterial-vector choice and collocation will pave a new way for gene therapy in the potential of tissue engineering and organ regeneration.

In this review, we emphasize the nonviral-vector biomaterials developed for gene delivery and their application in tissue regeneration and repair (Fig. 1). Advanced nonviral biomaterials, including lipid/lipid-like carriers, polymeric biomaterials, functional dendrimers, inorganic particles and exosomes, carry the targeting genes, such as encoding DNA (double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), plasmids DNA (pDNA)) and RNA (Messenger RNA (mRNA), MicroRNA (miRNA), small interfering RNA (siRNA)), into damaged tissues or sites for profitable gene therapy. On the other hand, we also highlight therapeutic applications of these advanced gene delivery materials in tissue regeneration, such as bone regeneration, cartilage regeneration, blood vessel regeneration, neuroregeneration and its broad potential in cancer-resected tissue repair and therapy. Finally, the strengths and limitations of different delivery vehicles are summarized in tissue regeneration and the review also shares our future perspectives in gene therapy and tissue regeneration. This will provide important information for advanced nonviral gene delivery materials in the potential of tissue engineering.

Fig. 1 Nonviral-mediated advanced functional carriers for precise and targeting delivery of different nucleic acids, including dsDNA, ssDNA, siRNA, miRNA, mRNA and so on. Advanced biomaterials, such as lipid/lipid-like carriers, polymeric biomaterials, functional dendrimers, inorganic particles and exosomes, are intensively investigated for efficient gene delivery and therapy

Nonviral-mediated gene delivery systems

The development of gene delivery and therapy

Gene delivery and therapy are considered to introduce exogenous normal or targeting genes (DNA or RNA) into objective cells to recompense for diseases aroused by defects and abnormal genes, so as to reach gene-related therapeutic purpose [36]. The conception of gene therapy is nominated in the early 1970s, the initial conceptualization is to interpose an accustomed gene to supersede a freakish gene [37, 38]. In 1990, the first clinical evaluation of a gene therapy approach to combating disease is launched at National Insititutes of Health (NIH) in the United States [39]. Since 2015, the worldwide gene therapy trade has flourished precipitately and also assessed that in 2025, the domestic and worldwide market of gene therapy will reach nearly 31 billion US dollars [40–42]. Therefore, gene therapy has been considered the third industrial revolution in bioloical medicine field after small molecule drugs and antibody drugs. Despite the rapid establishment of gene therapy, there are still rate-limiting steps, for example, the lack of efficient delivery system, weak sustained gene expression, and host immune reactions [43]. The Achilles’ heel of gene therapy is that how the targeting genes are effectively and accurately delivered into damaged sites for gene-mediated treatment. At present, gene delivery systems used in clinical trials are the basis for RV, LV, poxviruses, AV, AAV and herpes simplex virus (HSV) [44]. Nevertheless, inefficient delivery and transient gene expression are common issues with these vectors [45, 46]. The delivery system of advanced biomaterials will bring us a new dawn for desired gene therapy. Therefore, the development of drug delivery systems based on advanced functional biomaterials may serve as more effective drug and gene delivery vehicles for the treatment of harmful injury and malignant diseases. Moreover, we have also summarized the nonviral vectors under clinical trials or approved for human use currently (Table 1). The nonviral vectors have broadened human applications in the clinic.

Table 1 Nonviral vectors under clinical trials or approved for human use

Drug name	Modality	Disease or target	Vector property	Current clinical Phase	Vector component	Reference	
Patisiran	siRNA	TTR	lipid Nps	Approved,

2018

	DLin-MC3-DMA, DSPC, cholesterol, DMG-PEG 2000.	[47]	
mRNA-1273	Vaccine	SARS-Cov-2	lipid Nps	Approved,

2021

	DSPC, cholesterol, PEG2000-DMG, SM-102	[48]	
BNT162b2	Vaccine	SARS-Cov-2	lipid Nps	Approved,

2021

	ALC-0315, ALC-0159, DSPC, cholesterol	[49]	
RO7198457	Vaccine	Colorectal Cancer	lipid Nps	Phase II	DOTMA and DOPE	[50]	
CALAA-01	siRNA	RRM2	CD-containing

polymer

	Phase I, terminated	CD, PEG-AD, Tf-PEG-AD	[51]	
Notes TTR Transthyretin, PDAC Pancreatic ductal adenocarcinoma, RRM2 Ribonucleoside-diphosphate reductase subunit M2, DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine, DMG dimyristoyl glycerol, SM-102 9-Heptadecanyl 8-{(2-hydroxyethyl) [6-oxo-6-(undecyloxy) hexyl]amino}octanoate, ALC-0315 [(4-Hydroxybutyl) azanediyl]di (hexane-6,1-diyl) bis(2-hexyldecanoate), ALC-0159 2-[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide, DOTMA 1,2-di-O-octadecenyl-3-trimethylammonium propane, DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, CD cyclodextrin, AD adamatane, Tf human transferrin

Advanced gene nanocarriers/scaffolds in nonviral-mediated delivery systems

Many kinds of advanced biomaterials including lipid/lipid-like carriers, biopolymeric materials, functional dendrimers, inorganic biomaterials, exosomes and DNA nanostructures are designed and prepared to achieve efficient gene delivery and therapy [52, 53]. To improve gene delivery ability, there are various strategies based on targeting genes and advanced functional biomaterials to transfer exogenous genes and particles into impaired cells for transfection [54–56]. Common targeting genes contain encoding pDNA, mRNA, miRNA, siRNA, shRNA and circular RNAs (circRNAs) [57, 58]. Correspondingly, lipid carriers, cationic polymers, peptides, dendritic/branched materials and inorganic nanoparticles as gene delivery vectors are also performed well to enhance gene delivery and transfection. Moreover, extracellular vesicles (EVs) with the advantages of non-immunogenic, biodegradable, and biocompatible ability are considered as a promising delivery vehicle for various genetic therapeutics [59]. Lipid, lipid-like compounds and polymer compounds are one of the most intensively studied vectors for therapeutic gene delivery [60]. Herein, we will introduce these nonviral-mediated advanced biomaterials used for gene delivery and therapy in details.

Exosomes/DNA system

Extracellular vesicles (EVs) are regarded as small membrane vesicles to release into the extracellular matrix (ECM) and play an important role in regulating gene delivery and therapy [61, 62]. Exosomes with lipid-bilayer structure and the diameter of 40–160 nm are derived from different cells types, including stem cells, mast cells, epithelial cells, dendritic cells, B cells, T cells and cancer cells, to circulate in the extracellular environment [63, 64]. Exosomes from different cells have various functions and are applied in disease therapy [65, 66]. There are generally two forms of exosomes: One is biomimetic vesicles and the other is hybrid vescicles (Fig. 2A, B). For gene therapy, exosomes usually act as the efficient gene delivery system with versatile advantages, such as crossing biological barriers and genetically engineerable potential [67]. Yang and collaborators present an improved strategy to realize more efficient encapsulation and manageable release in recipient cells by encapsulating low-density lipoprotein receptor (Ldlr) mRNA into EVs [68]. There is an improved loading efficiency of Ldlr mRNA in EVs via MS2-MCP interaction [68]. Wood and collaborators also demonstrated that exosome-endogenous nanovesicles enable to transport short interfering (si)RNA to the brain in mice. GAPDH siRNA is specifically delivered by intravenously injected RVG-targeted exosomes to oligodendrocytes, microglia, neurons, causing a particular gene knockdown [69]. The integration of cell-derived EVs and synthesized polymers is further applied to complement targeting gene delivery capability. For instance, Gupta and collaborators successfully report a hybrid system of exosomes and PEI matrix (EPM) to provide high nucleic acid entrapment and protection from enzymatic degradation. The nanostructures can also enhance the specificity of delivery by combining a targeting ligand with no adverse response (Fig. 2C-E) [70]. In addition of the cell-derived EVs as gene delivery carriers, Li and collaborators develop a nanocarrier of CD44-specific ligand hyaluronic acid (HA)-modified milk-derived exosomes (mExo) encapsulated with folic acid (HA-mExo-FA). HA-mExo-FA could promote the apoptosis of activated LX2 cells and improve liver morphology and function alterations in zebrafish larvae (Fig. 2F, G) [71].

Exosomes are genetically engineered by the modification of polypeptide and nucleic acid to enhance the targeting gene therapy [63, 72]. For example, Liang and collaborators have fabricated an exosome-based chondrocyte-targeted miRNA (microRNA-140) delivery system for osteoarthritis (OA) therapy [73]. The chondrocyte-affinity peptide (CAP)-exosomes could carry miR-140 into profound cartilage sites through the dense mesochondrium to prevent cartilage-degrading proteases and slow down the OA progression. Moreover, exosomes can also transfer the CRISPR-Cas9 plasmids into targeting sites for gene therapy [74]. Kim and collaborators have reported that cancer-derived exosomes loaded CRISPR/Cas9 could restrain the expression of poly(ADP-ribose) polymerase-1 (PARP-1) to enhance the chemosensitivity of cisplatin and achieve satisfactory therapeutic effects in ovarian cancer tumors [75].

Fig. 2 Exosomes as gene delivery vectors and their biomedical applications in gene therapy. (A) The production of biomimetic vesicles derived from cells through extrusion/filtration method. (B) The biomedical application of exosomes. (C) Representative illustration of FA covalently attached to the exosome-polyethyleneimine matrix (EPM) as a transfer carrier for nucleic acid delivery. (D) The entrapment ability of EPM with siKRAS and siRNA. (E) Tissue distribution of bovine colostrum exosomes and EPM, with and without FA-functionalized exosomes. (C-E) Reproduced with permission [70]. Copyright 2021, Elsevier. (F) Schematic graph of HA and FA loading into mExo. (G) Scanning electron microscope (SEM) photos of mExo and HA-mExo-FA. (F, G) Reproduced with permission [71]. Copyright 2023, Wiley

Based on structural and chemical traits of EVs and DNA, DNA nanostructure is constructed by the complementary nature of the four nucleotide bases as well [76]. By precisely controlling the DNA hybridization, stable branched DNA self-assembly, DNA programmability and desired DNA-sequence synthesis, DNA nanoparticles are fabricated by decorating DNA structures and sequences to deliver the designed genes for gene therapy [77, 78]. Moreover, EVs can also be modified by DNA aptamers or other molecules to realize the target activity or other functions for broad potentials in clinic [79, 80].

Lipids

Lipid-induced gene delivery platform works for gene therapy due to the effect of cationic lipid molecules [81, 82]. In principle, the positive charges on head group could interact with the negative charges of nucleic acids to establish targeting lipid/gene complexes [83, 84]. Then, the lipid/gene complexes could fuse with cell membrane and eventually enter into the targeting cell for gene silencing or integration in gene-related disease treatment [85]. The commercial Lipofectamine 2000 and Lipofectamine 3000 are the most commonly transfection reagent with their characteristics of simple operation, easy acquisition and high transfection efficiency [86, 87]. For instance, when these two reagents are applied to deliver mRNAs into dorsal root ganglion (DRG) neurons, the transfection efficiency can reach up to 25% under the assistance of Lipofectamine 2000 transfection reagent [88].

In addition, lipid and lipid-like carriers are also used for delivery of both small nucleic acids (siRNA, miRNA) and large ones (pDNA, mRNA) [89]. Kranz and collaborators have reported that RNA-lipoplexes (RNA-LPX) with adjusted net-like structures could enter into dendritic cell (DC) populations and macrophages to realize stable gene expression of the encoded antigen for cancer immunotherapy [90]. Rajala and collaborators have also designed and synthesized an artificial virus by using the functional nanoparticles of liposome-protamine-DNA (LPD) complexes and modifying with cell permeable peptide or nuclear localization signaling (NLS) peptide, to deliver the targeting engineered genes for eye disease treatment [91]. The results revealed that LPD could encourage effective gene delivery in a cell specific manner and achieve the long-term expression of Rpe65 gene to Rpe65-lacking mice, thus inducing blindness correction in vivo [91]. Due to the specific advantages of lipids in easier design for ideal properties by altering lipid components, particle size and surface charges, lipids have more broad application potentials in gene delivery and therapy [92].

Cationic polymers

Similar to the mechanism of liposomes in gene delivery, cationic polymers also perform the delivery functions by the interaction with the negatively charged nucleic acids [93]. Cationic polymers with ionizable head groups can bind and condense DNA into small molecular structures to carry targeting genes for disease treatment [94]. Efficient transfer and cell internalization of DNAs are regulated through electrostatic interactions between cationic lipids and negatively charged nucleic acids or plasma membrane components [95]. For example, the amine-based cationic materials, including polylysine, polyamidoamine (PAMAM), PBAEs, poly(ethyleneimine) (PEI), cationic dendrimers, and chitosan, have also been explored as DNA vectors for gene delivery and therapy [96–98]. Among these cationic polymers, biofunctional PEI (50 kDa) supramolecular structures have demonstrated excellent transfection efficiency in vivo, compared to other amine-based polymers [99]. PEI serves as a classic and effective transfection agent for gene delivery. PEI possesses two structure forms, one is linear chain and another is branched chain, which can be synthesized at different condition (Fig. 3A) [100]. About 20% or 16.7% of the amino nitrogen is protonated at physiological pH [99, 101–103]. Besides, PEI has a high buffering capacity in a very wide pH range to escape from lysosomes and enhance the delivery productivity [104, 105]. Rohiwal and collaborators have constructed the targeting delivery strategy of CRISPR/Cas9 complexed PEI magnetic nanoparticles (MNPs) for gene therapy [106]. The 20-nm-in-diameter PEI-MNPs with sufficient colloidal stability show higher gene-editing efficiency, even compared with standard Lipofectamine transfection. To further improve the transfection efficiency, Lemaire and collaborators design and synthesize a depolymerized chitosan-polyethyleneimine DNA complex (dCS-PEI/DNA) for effective gene delivery (Fig. 3B). The results reveal that dCS-PEI/DNA complexes present the improved nucleic acid encapsulation ability, cellular uptake efficiency and transfer potency in human hepatoma HuH-7cells and murine primary hepatocytes (Fig. 3C) [107].

In addition of PEI-based gene carriers, PAMAM amino biomaterials are also applied as gene delivery vectors for efficient gene therapy. Volonterio and collaborators report the functionalization of the outer primary amines of PAMAM G2 and PAMAM G4 by building blocks bearing fluorinated moieties with a guanidino functional group. The obtained conjugates have the prominent advantages of improved transfection efficiency and negligible cytotoxicity (Fig. 3D) [108]. Nevertheless, poor biocompatibility, low biodegradability and high manufacturing costs greatly hinder their clinical applications for gene delivery and gene therapy.

Fig. 3 Cationic polymers as gene delivery vectors and their biomedical potentials. (A) PEI-based nanoparticle formation is designed by the admixing of PEI polymer derivatives (linear or branched) with nucleic acid cargos to encode for any genes of interest. (B) Schematic overview of ternary complex formation by sequential addition of core and shell polymer to the nanovector DNA. (C) In vitro evaluation of toxicity and transfection efficiency in HuH-7 cells. (B, C) Reproduced with permission [107]. Copyright 2023, Wiley. (D) Structural illustration of selectively fluorinated PAMAM–Arg conjugates and transfected cell micrographs. Reproduced with permission [108]. Copyright 2023, American Chemical Society

Inorganic materials

Inorganic materials are also implemented by biofunctional modification as gene delivery carriers for purposeful gene therapy. The commonly used inorganic nanoparticles (NPs) consist of carbon-based NPs (quantum dots, graphene, carbon nanotubes and nanofibers), metal-based NPs (gold, copper, silver), semiconductor-based NPs (germanium, iron oxide) and silica NPs (SiO2) [109]. These inorganic NPs can be functionalized by biophysical or biochemical modification to adjust specific size of inorganic NPs and endow unique surface properties for precisely targeted gene delivery and therapy [110].

To enhance gene delivery ability of inorganic NPs, gold NPs are modified with nucleic acids via covalent or non-covalent conjugation through thiol moieties [111–114]. Dai and collaborators have fabricated the Janus gold/chitosan (J-Au-CS) NPs to realize fluorescence imaging-guided photothermal therapy (PTT) and PTT-enhanced gene therapy for cancer therapy [115]. Mesoporous silica nanoparticles (MSNs) with the diameter of 100–250 nm have also been used in gene delivery due to its good biocompatibility, porous size controllability and stable aqueous dispersion [116–118]. These MSNs are usually loaded with targeting genes by the means of weak non-covalent interactions [119]. Rasool and collaborators have also developed a thiolated, bioactive mesoporous silica NPs to improve the cell adhesion property in bone tissue regeneration [120]. The results reveal that MSN-SH groups can increase calcium deposition and induce osteogenesis by altering the bone-related gene expression [120]. Although inorganic materials play a vital role in gene delivery and therapy, especially in the cargo-loading ability and gene release rate, the toxicity and degradability are still unavoidable problems for gene delivery in vivo [121]. Some studies have demonstrated that gold and iron oxide nanoparticles are regarded as ideal non-toxic carriers for tissue regeneration and disease therapy [116, 122]. Moreover, the metabolism of these inorganic materials remains still a matter of concern in gene delivery.

Proteins and peptides

Protein and peptide-based formulations are also important delivery carriers, which usually consist of 5–30 amino acids with mostly hydrophobic and/or positively charged side chains [123]. Cell-penetrating peptides (CPPs) or homing peptides are typically representatives for gene delivery [124]. Positive charge in proteins and peptides can interact with negative charge by the means of covalent or non-covalent binding to enter into the cells [125]. Wang and collaborators have designed and prepared a library of glutathione (GSH)-responsive silica nanocapsules (SNCs), which could systemically deliver SNCs conjugated with glucose [126]. Under glycemic control, rabies virus glycoprotein peptide enables to bypass the intact blood-brain barrier (BBB) to achieve brain-wide transfer of various biologics and CRISPR genome editors can target various genes in both wild-type mice and Ai14 reporter mice [126]. Nevertheless, endowing CPPs with targeting ability and decreased toxicity remain great advantages for gene delivery of proteins and peptides in clinical potential.

In summary, DNA condensation, protection from nuclease, cell targeting, endosomal disruption, and nuclear translocation are the key factors for a successful gene delivery vector. For mechanism of biomaterials-based vectors entry into cells, most polymer/DNA complexes are uptaken into membrane-bound compartments by pinocytosis, adsorptive endocytosis, receptor-mediated endocytosis, or phagocytosis. After entering into the cells, they will escape from endosomal degradation using endosomolytic peptides or osmosis, and possibly obtain nuclear entry via an active nuclear skeleton mechanism. Therefore, cell-specific targeting ligands have been designed to link polymeric vectors to enhance the cell targeting efficiency by improving receptor-mediated endocytosis. For example, transferrin, monoclonal antibody, mannose, galactose, lactose, folic acid, low-density lipoproteins, and RGD peptides are the cell-specific targeting ligands to improve cellular internalization and gene transfection. In addition, biomaterial-mediated nonviral gene vectors also show respective advantages and disadvantages in gene delivery, including exosomes, lipids, cationic polymers, inorganic materials, proteins and peptides (Table 2).

Table 2 Advantages and disadvantages of biomaterial-mediated efficient nonviral gene delivery

Biomaterials-based vectors	Types	Advantages	Disadvantages	
Exosomes	Extracellular vesicle	Wide source from various cell types

Low immune inflammatory reaction

Easy modification

	Complicated operation

Low production yield

	
Lipofectamine 2000/3000	Lipid	Good stability and low degradation

Large-scale commercialization

High gene transfection efficiency

	Cytotoxicity in vivo

Inflammatory reaction

	
PLL	Cationic polymer-based systems	Aggregation under physiological conditions	Low solubility of PLL/DNA complexes in aqueous media; cytotoxicity; undesirable effect of aggregation of PLL/DNA complex	
PEI	Cationic polymer-based systems	Condense plasmids into colloidal particles that effectively transfect pDNA into a variety of cells both in vitro and in vivo; High transfection efficiency	Prone to aggregation and are toxic to the cell and cytotoxicity	
Chitosan	Cationic polymer-based systems	Nontoxic biodegradable polysaccharide	Not so high efficiency	
Dendrimers	Cationic polymer-based systems	The transfection efficiency dependens on the size, shape, and number of primary amine groups	Unstable	
Quantum dots, graphene, carbon nanotubes or nanofibers	Carbon-based inorganic materials	High gene transfection efficiency

Stability

High production in industry

	Aggregation

Cytotoxicity

Degradation

	
Gold, copper, silver	Metal-based inorganic materials	High transfection efficiency

Simple modification

	Cytotoxicity in vivo

low degradation

	
Peptides with hydrophobic or positively charged side chains	Proteins and peptides	Low immune inflammatory reaction

High gene transfection efficiency

Nontoxic biodegradable materials

	Complicated operation

Unstable

Biological safety

	

Gene therapy for tissue regeneration

Gene therapy serves as a crucial role in modulating tissue regeneration and repair [127]. Regeneration is the process of self-renewal and repair by which a partial organism replaces lost or damaged tissue. Regenerative capacity widely varies across species, tissues, and life stages, and the process is also genetically programmed to accomplish injured tissue repair [128]. In the evolution of tissue regeneration, gene therapy can achieve point-to-point precise and targeted therapeutic effect of tissue repair through the transfer of genetic materials [129, 130]. The activity of DNA regulatory elements, transcription factors and chromatin regulators co-determine regeneration programming for tissue engineering [128]. For tissue regeneration, the targeting precision is critical to obtain the high efficiency and safety of gene therapy for disease diagnosis indications, such as tissue damage [130]. Yan and collaborators have found that tissue regeneration enhancer elements (TREEs) isolated from zebrafish can direct targeted, injury-associated gene expression from viral DNA vectors delivered systemically in small and large adult mammalian species [131]. These findings indicate that targeting gene delivery and therapy present huge potentials in tissue regeneration and repair.

Tissue regeneration and repair

Tissue Engineering is a new discipline emerging in recent years, which belongs to the category of biological high technology [6, 132]. The term of tissue engineering is firstly proposed at the Bioengineering Group Meeting held by the American Science Foundation in Washington in 1987. It is officially defined in 1988 as: Combing the basic principles and new technologies of life science and engineering to correctly understand the normal and pathological conditions of mammals. On the basis of the relationship between tissue structure and function in the two states, it is an emerging discipline to study and develop biological substitutes for repairing, maintaining, and promoting the functions and forms of various tissues or organs of the human body after damage [6, 8]. Specially, tissue regeneration has ushered in vigorous process with the development of nanomedicine engineering and gene therapy in recent years.

Tissue engineering is divided into four aspects: Cell seeding and culture, advanced functional biomaterials for mimicking cell microniches, techniques for creating tissues and organs, and clinical utilization of tissue engineering [133, 134]. Currently, three approaches are constructed for tissue repair in clinical practice: (i) autologous tissue transplantation, (ii) allogeneic tissue transplantation, and (iii) the application of artificial substitutes [130, 135]. The three methods are respectively deficient and confronted with some mutual problems, such as immune rejection and donor shortage. The development of tissue engineering will fundamentally solve the problem of dysfunction or loss of treatment caused by tissue and organ defects [135]. The decisive essence of tissue engineering is to establish a three-dimensional (3D) space complex composed of cells and bioactive materials, which is radically different from traditional two-dimensional (2D) structures, such as cell culture patterns, nutritional supplement modes and 3D microenvironment niches [136, 137]. Therefore, the basic principles of tissue regeneration are: (1) simple reconstruction of tissue shape, structure and function to achieve permanent replacement, (2) abundant usage of least tissue cells to repair large tissue defects after in vitro culture and expansion, and (3) arbitrary geometry switching according to the tissue and organ defects to achieve a perfect shape repair [138].

Advanced gene nanocarriers/scaffolds for gene therapy in tissue engineering

Advanced functional biomaterials can act as gene carriers and regulators to deliver targeting genes or growth factors into corresponding damaged tissue sites to achieve tissue regeneration [139]. The tissue regeneration related cells, including progenitor cells, induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs) and mesenchymal stem cells (MSCs), can interact with the advanced biomaterials and promote the expression of some functional proteins related to cell anchoring junction (Fig. 4) [140–144]. The expression of collagen, fibronectin and laminin demonstrates the formation of adhesion anchorage between cells and extracellular matrix (ECM) [145, 146]. The transmembrane adhesion protein, integrin primarily binds collagen and fibronectin to produce adhesion sites for cell attachment, which is beneficial for migration, division and differentiation of stem cells in the process of tissue regeneration [147–150]. It can also connect a series of intracellular anchor proteins, such as talin, vinculin and β-catenin for cell spreading and adhesion [151–154]. Eventually, talin, vinculin, and β-catenin interacted with other molecules to form physical bridges, can alter the cytoskeleton and nuclear transcription to promote functional cell fate [155]. At the same time, gene editing (i.e. knock in and knock out of targeting genes) is also taken up in this process to enhance gene therapy in tissue regeneration [156, 157]. According to the discussion of gene therapy in tissue regeneration, gene therapy based on advanced functional gene delivery materials can play a vital role in tissue engineering and repair, such as bone regeneration, cartilage regeneration, blood vessel regeneration, nerve regeneration and repair (Table 3).

Fig. 4 ECM remodeling and skeleton-mediated cellular nanomechanics enhance gene delivery through activation of force-sensing-related signaling pathways. Interaction of tissue regeneration related cells, including progenitor cells, iPSCs, ESCs and MSCs with advanced biomaterials to promote the expression of some functional proteins related to cell anchoring junction, such as collagen, fibronectin and laminin. These proteins can connect a series of intracellular anchor proteins, such as talin, vinculin and β-catenin for cell spreading and adhesion to alter the cytoskeleton and nuclear transcription to promote cell migration, division and differentiation and functional cell fate. Gene editing (knock in and knock out of targeting genes) also participate in this process to enhance gene therapy ability in tissue regeneration

Table 3 Advanced gene/drug nanocarriers for gene therapy in tissue engineering

Application in tissue engineering	Therapeutic nucleic
acids	Delivery vectors	Therapeutic outcomes	Ref.	
Bone regeneration	pVEGF/pBMP2	Collagen-nanohydroxyapatite scaffold	Complete bridging of the defect after 4 weeks	[158]	
Bone regeneration	miR-21a-5p	BMSCs derived exosomes	Promoted osteogenesis and osseointegration	[159]	
Bone regeneration	Asp8-EM/miR-26a	Exosome-mimetics	Promotes bone regeneration in bone defect and osteoporosis models	[160]	
Cartilage regeneration	pTGF-β1	Cupper sulfide@phosphatidylcholine	Efficient than commercial transfection agent	[161]	
Cartilage regeneration	miR-224-5p	Transfected nanoparticles	Enhance miR-224-5p delivery ability	[162]	
Cartilage regeneration	microRNA	Glycosaminoglycan-binding enhanced transduction (GET) NPs	Enhance cartilage defect repair	[163]	
Blood vessel regeneration	Circ-Snhg11	Exosome-embedded GelMA (GelMA-Exo) hydrogels	Increase the survival of endothelial cells to maintain endothelial cell (EC) function	[164]	
Blood vessel regeneration	miR-22	Laponite hydrogels	Reduce the infiltration of the macrophages and reverse the adverse vascular ECM remodeling	[165]	
Blood vessel regeneration	miR-126	Poly(ethylene glycol)-b-poly(l-lactide-co-ε-caprolactone) (PELCL)	Improve endothelialization ability in vivo	[166]	
Neuroregeneration	MiR-221/222	Cationic polymer (PDAPEI)	Promoted nerve regeneration after sciatic ne	[167]	
Neuroregeneration	siRNA	polybutylcyanoacrylate nanoparticles (CaspNPs)	Restoration of central visual system damage	[168]	
Neuroregeneration	Vector DNA	PEI/DNA polyplexes	Protein expression was detected in 82.8% ± 1.70% of DRG neurons	[169]	

Advanced gene nanocarriers/scaffolds for gene therapy in bone regeneration

Long-distance bone defects, caused by trauma, tumor resection, and infection remain a worldwide concern due to the autologous regeneration insufficiency and alloimmune reaction. To date, the “gold standard” for bone defect repair is autologous bone grafting in clinic [170, 171]. Nonetheless, the extended treatment time at the graft donor site, significant pain, and increased treatment costs are the major limitations for bone regeneration [172]. On the other hand, bone allografts have the inevitable risk of immune rejection and bone size mismatch [173]. Moreover, metal bone implants have the drawbacks of poor osseointegration [174]. Therefore, the development of tissue-engineered bones based on the combination of efficient gene therapy has broad prospects in recent years.

Gene therapy is considered as an ideal way in many ways to enhance bone regeneration ability due to precisely targeting bone repair. Gene therapy is interpreted to transfer specific gene products to precise anatomical positions [175, 176]. In addition, transgene expression level and expression duration can be modulated with existing techniques [177]. For bone regeneration, genes of interest are transferred to the fracture locations, and expressed at suitable levels, and then inactivated after fracture healing [178]. The transmission of biological factors, primarily bone morphogenetic proteins (BMPs), has produced encouraging results in both animal and clinical studies [179]. A great deal of work has also been done on exploring previously defined growth factors and inventing new growth factors [158]. To enhance gene therapy capacity, gene delivery systems are designed from viral and nonviral vectors to tissue-engineered scaffolds to make significant progress [159]. Despite some public hesitation about gene therapy, this technology has huge potential applications to broaden our horizons to cure a wide range of human skeletal or musculoskeletal disorders.

Nonviral-mediated gene vectors contain chemical delivery and physical delivery methods [180]. Chemical delivery is mainly to complex cationic biomacromolecules or lipids with DNA/RNA to induce the electrochemical repulsion with cell membranes [160]. Physical methods of electroporation and sonoporation take advantage of electrical and mechanical energy respectively to build transient pores in cell membranes for efficient internalization of exogenous DNAs [56, 181]. Curtin and collaborators have reported a nonviral dual delivery system of vascular endothelial growth factors (VEGF) and bone morphogenetic protein 2 (BMP2) in a collagen-nanohydroxyapatite (nHA) scaffold, which reveals a marked 36-fold increase in bone formation in nHA scaffold versus the empty defect as early as 4 weeks post-implantation underlining the immense ability in bone regeneration [182]. In this scaffold, nHA particles and PEI are used to serve as nonviral vectors to achieve pDNA delivery for efficient gene therapy [182].

Fig. 5 Biomaterials-based gene delivery vectors for bone regeneration. (A) Non-coding-RNA-activated core/chitosan shell nanounits coated with polyetheretherketone with the ability to promote bone regeneration. (B) Micro-CT images demonstrating bone regeneration surrounding implants, as well as reconstructed 3D images of samples and new bone. The color yellow denotes samples, whereas the color red represents fresh bone regeneration. Quantitative bone analysis 8 weeks after implantation. (A-B) Reproduced with permission [183]. Copyright 2023, American Chemical Society. (C) CRISPR activation of DANCR promotes calvarial bone formation. (D) µCT analysis of in vivo calvarial bone repair. 3D projection of osteomized sites of mock and Bac-Sa-VPR groups (left) and frontal views of osteomized sites (right). (C-D) Reproduced with permission [184]. Copyright 2021, Elsevier. (E) Schematic diagram of conjugating Asp8 to exosomal amine groups by click chemistry reaction. (F) H&E staining and Masson’s trichrome staining analysis of defect sites at 2 weeks, scale bar = 100 μm. (E-F) Reproduced with permission [185]. Copyright 2023, Elsevier

Advanced functional biomaterials can serve as gene delivery carriers for gene therapy in bone regeneration. Li and collaborators develop non-coding-RNA-induced core/chitosan shell nanounits to improve bone incorporation by immunoregulation (Fig. 5A). miMT-PEEK contributed macrophage M2 polarization via the NF-κB pathway to enhance BMSCs osteogenic differentiation. In vivo, miMT-PEEK increases osteogenesis and osseointegration, verified by Micro-CT images and histological images (Fig. 5B) [183]. Moreover, Hu and collaborators firstly verify that DANCR expression promotes rASC chondrogenesis. Then, the CRISPR activation (CRISPRa) technology is conducted to upregulate endogenous DANCR, promote rASC chondrogenesis and increase calvarial bone healing in rats (Fig. 5C). The µCT analysis in vivo also verifies the effect of DANCR NPs on calvarial bone repair (Fig. 5D) [184]. Further, Zhao and collaborators have designed Asp8-EM/miR-26a to enhance the synergetic effects for bone regeneration with increased targeting ability by Asp8 modification in bone defect and osteoporosis models (Fig. 5E-F) [185]. Therefore, the nonviral-mediated gene delivery system can regulate gene therapy ability in bone regeneration and make great achievement for clinical potential.

Advanced gene nanocarriers/scaffolds for gene therapy in cartilage regeneration

Advanced gene delivery biomaterials are applied to control targeting gene delivery efficiency into desired damaged sites for gene therapy and cartilage regeneration [186]. For instance, untreated damage to articular cartilage often results in osteoarthritis to induce inevitable disability [187]. Bone-marrow stimulation procedures, autologous or allograft, and periosteum transplantation are the main treatment methods in clinic for cartilage repair, for example, CuS/TGF-β1@PC NPs are prepared to deliver genes for cartilage regeneration [161, 188]. Nevertheless, these processes are usually accompanied by surgical trauma and poor long-term efficacy. Besides, the limited availability of donor sites and immune rejection may also restrict the broad application of gene therapy in cartilage regeneration [189]. Therefore, new comprehensive cartilage repair strategies are urgently needed based on efficient gene delivery and therapy. Advanced biomaterials-guided gene delivery provides the novel solution for precise delivery to direct targeted gene therapy [190]. Up to now, inorganic NPs, liposomes and cationic polymers are the commonly used biomaterials for gene delivery in cartilage regeneration [190]. These NPs can spatiotemporally enhance the process of cartilage repair by improving gene delivery ability [191]. Based on the superiority, the designed strategies of different biomaterials are also introduced and their important role is highlighted in gene therapy for cartilage repair.

Fig. 6 Biomaterials-based gene delivery vectors for cartilage regeneration. (A) Schematic illustration of the preparation of the Cu-based NPs. CuS NPs are reacted with ATPES to obtain CuS-NH2 NPs, and then electrostatically bonded with negatively charged TGF-β1 pDNA. Then PC is coated on the NPs for biomimetic modification. (B) Representative images of Safranin-O/Fast green staining and Toluidine blue staining of the knee joints after different treatments. (A-B) Reproduced with permission [162]. Copyright 2021, Elsevier. (C) The silencing of miR-221 in combination with TGF-β3 improved sGAG distribution. Representative histological images of cell-seeded scaffolds stained with (A) hematoxylin and eosin and (B) thionine after 28 days in culture +/− TGF-β3 supplementation. Scale bars represent 100 μm length. (D) Representation of GET peptide: a glycosaminoglycan (GAG)-binding peptide sequence (P21), fused to an amphiphilic region with an octa-arginine (8R) and a cell-penetrating peptide (CPP). (E) The incorporation of miR-221 inhibitor to CI/II-HyA scaffolds reduced the expression of miR-221 by hMSCs. (C-E) Reproduced with permission [200]. Copyright 2021, Wiley

Inorganic NPs occupy an important position in gene delivery and therapy for cartilage regeneration [192]. Cai and collaborators have designed and synthesized the biomimetic cupper sulfide@phosphatidylcholine (CuS@PC) NPs loaded with pDNA encoding transforming growth factor-beta 1 (TGF-β1) to operate MSCs for increased osteoarthritis treatment via cartilage regeneration (Fig. 6A, B) [162]. CuS/TGF-β1@PC NPs are more efficient than commercial transfection agent for gene delivery and present increased cell migration, chondrogenesis and inhibition of ECM degradation [162]. However, the low transfection efficiency and potential cytotoxicity restrict its further development and application in clinic. To detour these disturbances, liposomes have been widely recognized as a commercial transfection reagent for efficient gene delivery due to good biocompatibility [193]. At the same time, the influence of polymer-based carriers on gene delivery and therapy for cartilage repair are also studied and applied in gene delivery process [190]. For instance, hydrogels become research hot spot for gene delivery and therapy [194]. Dong and collaborators have developed an injectable chitosan/silk fibroin hydrogel for cartilage repair, which could release stromal cell-derived factor-1 (SDF-1) and kartogenin (KGN), in turn to enhance the recruitment and chondrogenic differentiation of MSCs spatiotemporally [195]. For autologous treatment, the poor regenerative ability of adult cells and the inflammatory state of the injured joint are the main obstacles. Bonato and collaborators have also encapsulated the TAK1-KO (TGF-β-activated kinase 1 knockout) chondrocytes into a hyaluronan hydrogel to deposit copious cartilage extracellular matrix proteins and facilitate integration onto native cartilage, even under proinflammatory conditions [163]. In another study, Chen and collaborators have used polyamidoamine dendrimer with amino acids as efficient vectors to deliver microRNA-224-5p (miR-224-5p), and the vector could condense miR-224-5p into transfected nanoparticles, which can show higher cell internalization and transfer ability compared to Lipofectamine 3000, and also protect miR-224-5p from RNase degradation to enhance miR-224-5p delivery ability [196].

Organic/inorganic nanohybrids also serve as multifunctional gene delivery systems in cartilage regeneration [197]. In particular, nanohybrids comprising of cationic polymers and inorganic NPs are considered promising candidates as advanced functional gene delivery system [198]. To promote gene delivery and therapy efficiency, glycosaminoglycan is designed as advanced gene delivery carriers for cartilage regeneration [199]. Claudio and collaborators have fabricated the microRNA (miR)-activated scaffolds, in which glycosaminoglycan-binding enhanced transduction (GET) NPs system is used to encapsulate the miR-221 inhibitor (Fig. 6C-E) [200]. The miR-activated scaffolds can successfully transfect human MSCs with the miR-221 cargos in a sustained and controlled manner up to 28 days, which is promising to enhance cartilage defect repair. Nucleic kinase substrate short peptide (pNNS)-conjugated chitosan (pNNS-CS) is also applied to improve gene delivery and therapy ability for cartilage repair [201]. Zhao and collaborators have reported the enhanced transfection efficiency of a pDNA-chitosan (pDNA-CS) complex using a phosphorylatable nuclear localization signal-linked nucleic kinase substrate short peptide (pNNS) conjugated to chitosan (pNNS-CS) [202]. On the other hand, they also investigate the effects of pNNS-CS-mediated miR-140 and IGF-1 in both rabbit chondrocytes and cartilage defects model. The results indicate that pNNS-CS serves as an excellent gene delivery vector in gene therapy for cartilage defects and that miR-140 combination with IGF-1 transfection has better biological effect on cartilage defects.

Exosomes are one of the most popular gene delivery vehicles, especially for cartilage regeneration and repair [203]. Mao and collaborators have suggested that exosomal microRNA-92a-3p (miR-92a-3p) can regulate cartilage development and homeostasis by directly targeting WNT5A [204]. Exosomal miR-92a-3p may act as a Wnt inhibitor and exhibit the potential as a disease-modifying osteoarthritis drug. In addition, Xu and collaborators have also reported that BMSC-Exos can deliver miR-326 to chondrocytes and cartilage to improve OA by targeting HDAC3 and STAT1/NF-kappa B p65 to inhibit pyroptosis of chondrocytes and cartilage [205].

Although biomaterial-based gene therapy has achieved great success in cartilage regeneration and repair, there are little nonviral vectors to achieve extremely high transfection efficiency [190, 206]. It is still an important task to improve transfection efficiency as much as possible on the premise of ensuring safety [190]. In addition, it is necessary to enhance the matching ability of gene release with the various stages of the chondrogenesis process [207]. Therefore, once these shortcomings are solved, it still can’t stop biomaterial-based gene therapy from representing the future direction for cartilage regeneration.

Advanced gene nanocarriers/scaffolds for gene therapy in blood vessel regeneration

Angiogenesis, the growth of new vessels, is a vital process for tissue regeneration of circulation research [208]. During the process of blood vessel regeneration, advanced biomaterial-based nonviral vectors play a vital role in regulating gene delivery and therapy. Among them, inorganic NPs, liposomes and cationic polymers are common gene carriers for blood vessel regeneration [52, 208].

Mesoporous silica NPs are considered as gene therapy vectors and used in blood vessel regeneration [164]. To enhance delivery ability of mesoporous silica NPs, Wang and collaborators have investigated that mesoporous silica NPs-encapsulated miR-124 inhibitor increases the expression of SCF/c-kit protein by targeting P2Y(12) to improve the regeneration of cerebral blood vessels in lacunar cerebral infarction [165]. Although inorganic materials present the significant power in controlling gene delivery and therapy, the degradation and metabolic toxicity are still not negligible [209]. Alternatively, polymer-based gene therapy is showing huge advantages at this time. For instance, hydrogel scaffolds have the important influence on gene delivery [210]. Hu and collaborators have constructed exosome-embedded GelMA (GelMA-Exo) hydrogels with the ability of promoting diabetic wound healing, which could also deliver circ-Snhg11 and thereby increase the survival of endothelial cells to maintain endothelial cell (EC) function by activation of miR-144-3p/NFE2L2/HIF1α signaling pathway (Fig. 7A) [166]. Further, Zheng and collaborators have also found that the miR-22 loading laponite hydrogels inhibit the neointimal formation to reduce the infiltration of the macrophages and reverse the adverse vascular ECM remodeling by the upregulation of miR-22 and downregulation of its target genes methyl-CpG binding protein 2 (MECP2), which may offer a novel strategy to treat cardiovascular diseases (Fig. 7B, C) [211]. Polymer-based nanofibers also serve as a common delivery vector for gene delivery [212, 213]. Zhou and collaborators have fabricated a bilayer vascular scaffold via emulsion electrospinning of poly(ethylene glycol)-b-poly(l-lactide-co-ε-caprolactone) (PELCL), dual-power electrospinning of poly(ε-caprolactone) (PCL) and gelatin (Fig. 7D) [214]. The results demonstrate that the inner layer of PELCL loading with miR-126 could improve endothelialization ability in vivo. Local delivery of miRNA-based nanofibers may be an effective method to facilitate blood vessel regeneration [213, 215]. Maryam and collaborators have found that incubation of human endothelial cells (HUVECs) with polyhedral oligomeric silsesquioxane NPs (POSS NPs) could contribute to the modulation of angiogenesis and exosome biogenesis, which benefits to angiogenesis [216]. Some different types of polymer materials, for example, poly(L-lactic acid) (PLLA), poly(L-lactic acid)-co-poly(-caprolactone) [P(LLA-CL)] and eN-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, also play a crucial role in regulating gene delivery and therapy for blood vessel regeneration [217, 218].

Fig. 7 Biomaterial-based gene delivery vectors for blood vessel regeneration. (A) Hypoxia-pretreated ADSC-derived exosome-embedded hydrogels promote angiogenesis and accelerate diabetic wound healing. Reproduced with permission [166]. Copyright 2023, Elsevier. (B) The gelation of the laponite hydrogels in vitro. (C) Co-staining of the injured rat common carotid arteries with eNOS and αSMA 14 days after the treatment with the miR-22 loading laponite hydrogels. (B, C) Reproduced with permission [211]. Copyright 2022, Elsevier. (D) Morphology of the prepared vascular scaffold. SEM micrograph of the cross section and larger magnification. Reproduced with permission [214]. Copyright 2016, Elsevier

Polymer-based gene delivery materials can not only take part in gene delivery and therapy, but also control many other processes of endothelial cells, for example, nanocarriers with good biological activity due to surface and volume effects are more conducive to gene loading, cell adhesion and proliferation [219]. For hydrogel scaffolds, they can offer the possibility of sustained blood vessel regeneration [220]. Further, the binding and migration ability of transfected cells is limited in hydrogels for blood vessel regeneration [221]. Therefore, polymer-based materials allow the combination of multiple components and forms, and the integration of multiple materials has become the next development direction of biomaterial-mediated gene therapy.

Advanced gene nanocarriers/scaffolds for gene therapy in neuroregeneration

Peripheral nerve injuries (PNIs) are frequently encountered in clinical practice [222]. Short distant defected peripheral nerve can regenerate by repairing and suturing, but the repair of long distant nerve defect is still a global problem [223]. Currently, the autologous nerve graft is the gold standard treatment for long-distance nerve defect [223]. However, some challenges remain pendent for PNIs repair, such as sensory loss, scarring, and neuroma formation at the donor site [135, 167]. Moreover, size and fascicle mismatch, tubercle, and fibrosis also limit their applications in neuroregeneration [167]. To solve these problems, gene therapy has been applied in neuroregeneration and reported for nerve regeneration [224]. It is imminent to develop efficient biomaterial-based gene delivery vectors for high transfection efficiency of neuronal cells [225]. An overview of studies about neuronal cell transfection approaches, nonviral-vectors and their transfection efficiencies are summarized in Table 4.

Table 4 Nonviral-mediated delivery of nucleic acids for nerve system repair

Delivery methods	Therapeutic nucleic
acids	Delivery vectors	Therapeutic outcomes	Ref.	
Intrathecal administration	Plasmid DNA	Polyethylenimine (PEI)	Prolonged transgene expression in the spinal cord	[226]	
Injection	MiR-221/222	Cationic polymer (PDAPEI)	Promoted nerve regeneration after sciatic nerve crush	[227]	
Injection	siRNA	Chitosan/siRNA nanoparticle	A reduction of 65–75% of targeted mRNA and neurite outgrowth was improved	[228]	
Scaffold implantation	MicroRNA-222	Chitosan nanoparticles with silk fibroin (SF) nanofibrous scaffolds	Enhance neuronal differentiation of neural stem cells	[229]	
Intrathecal injection	mRNA	(PEG)-polyamino acid block copolymer	Sustained protein expression in the cerebrospinal fluid for almost a week	[230]	
Tail vein injection	siRNA	Extracellular vesicles	Enhancing the therapeutic effects on SCI	[231]	
In vitro transfection	miR-21a	Exosomes	Achieve their therapeutic effects in promoting neurogenesis	[168]	
Subcutaneous injection	miR-100	Nanovesicles	Promotion hair follicle growth	[169]	
Scaffold implantation	Small non-coding RNAs	Nanofibers-hydrogel scaffold	Aligned axon regeneration	[232]	
Scaffold implantation	pDNA	biodegradable polycations	Enhancement recovery of hindlimb motor function	[233]	
Intraocular injections	siRNA	polybutylcyanoacrylate nanoparticles (CaspNPs)	Restoration of central visual system damage	[234]	
Intrathecal injection	Vector DNA	PEI/DNA polyplexes	Protein expression was detected in 82.8% ± 1.70% of DRG neurons	[235]	

Liposomes as a commercial reagent work through the effects of cationic lipid molecules [236]. The molecules containing positive-charge head groups can interact with negative-charge nucleic acids to form the complexes [237, 238]. Then, the complexes fuse with the cell membrane and efficiently deliver the nucleic acids into cells for gene therapy [85]. Liposomes have low toxicity and stable transfection ability for gene delivery, and may be further applied for neuron regeneration and repair in vivo [89, 239].

Cationic polymers have caused intense attention in nerve regeneration [240]. Shi and collaborators have studied the effect of intrathecal administration of pDNA/PEI complex into the lumbar subarachnoid space and the result is satisfactory for high efficient gene delivery [226]. Some researchers have proposed the modification of PEI by polyethylene glycol (i.e. PEGylation) could improve biocompatibility [241]. Song and collaborators have reported a biodegradable and biocompatible cationic polymer (PDA/PEI) by cross-linking low molecular weight PEI (1.8 kDa) with 2,6-pyridinedicarboxaldehyde [242]. During the transfection process, PDA/PEI shows a lower cytotoxicity and higher transfection efficiency than PEI (25 kDa) in transfecting miR-221/222 into rat Schwann cells (SCs) [227]. Due to the toxicity of PEI and its modified polymers, natural polysaccharides (i.e. chitosan) are chosen as gene vectors for gene delivery and therapy [243]. Chitosan with biocompatibility, biodegradability and low toxicity have attended more and more attraction in gene delivery for nerve regeneration [244, 245]. Mittnacht and collaborators have fabricated the polymer filaments loaded with chitosan/siRNA nanoparticles to promote nerve regeneration. There is a reduction of 65–75% of targeted mRNA and neurite outgrowth is improved [228]. Scaffold-mediated nonviral gene delivery for nerve regeneration also takes an important position in regulating gene therapy [243]. Li and collaborators have incorporated the microRNA-222 loading chitosan NPs (miR-222/CS NPs) with silk fibroin (SF) nanofibrous scaffolds to enhance neuronal differentiation of neural stem cells [229]. Sustained release and delivery of miR-222 in SF-based scaffold can improve the chance of successful gene transfection.

Gene therapy for cancer-resected tissue repair

Cancer gene therapy

Cancer is an unsolved worldwide problem due to high morbidity and mortality [246]. Cancer gene therapy refers to the delivery of therapeutic genes to target cells through appropriate carriers to precisely control expression up-regulation/down-regulation of specific tumor-related genes, so as to achieve efficient cancer treatment [247, 248]. The regulation process of gene and protein expression using RNA/nucleic acid in cancer therapy is essential for cancer-resected tissue repair (Fig. 8). Once genes are delivered into the targeting cells, RNA macromolecules can utilize diverse intracellular molecules to adjust gene and protein expression [249]. Then, the tumor suppressor gene is highly expressed and acts on cells to induce tumor cell apoptosis for cancer gene therapy. After the treatment of cancers, a tissue defect is exposed and it is difficult to heal damaged tissue [250, 251]. Therefore, gene therapy for cancer-resected tissue repair is demanded to coordinate tumor treatment and tissue regeneration [252, 253].

To enhance the cancer therapy efficiency and tissue repair ability, many researchers pay more attention on the inorganic NPs as gene delivery vectors for gene therapy [254]. Cristofolini and collaborators have fabricated a multifunctional hybrid NPs as magnetic delivery system for siRNA targeting the HER2 gene in breast cancer cells for efficient gene therapy and wound healing [255]. Kara and collaborators have also developed a novel poly-L-lysine (PLL)-modified sericin-coated superparamagnetic iron oxide NPs (PLL/Ser-SPIONs) as siRNA carriers [256]. PLL/Ser-SPIONs can act as a safe and promising carrier candidate to deliver siRNA-based genes into cells to treat cancer cells and induce tissue development for further applications in gene therapy and tissue engineering [256]. However, the major disadvantages of inorganic NPs are non-degradable nature, and entrapment by the lungs, liver, and kidneys, which is difficult for in vivo gene therapy in clinic [257].

In addition of inorganic NPs, the commonly used positive-charge polymers including PLL, PEI, polyamide (PAMAM), and poly(β-amino ester) (PBAE), which can interact with the negative-charge phosphate groups on the main chain of RNA and form complexes into cells and realize escape of RNA-bound endosomes [258–261]. Among them, PEI serves as a classic and effective transfection agent for gene therapy in cancer and tissue regeneration [99, 101–103]. In addition, PEI has a high buffering capacity in a very wide pH range. Chen and collaborators have reported the cationic perfluorocarbon nanoemulsions with positive surface charge provided by a fluorinated PEI (F-PEI) [262]. The fluorinated emulsion (F-PEI@PFD) with reduced cytotoxicity can enhance cellular uptake and improve endosomal escape of the siRNA for gene delivery and therapy in cancer-resected tissue engineering.

Fig. 8 Regulation of gene and protein expression using RNA/Nucleic acid in cancer therapy for tissue regeneration. Once delivered into the cells, RNA macromolecules can utilize diverse intracellular mechanism to control gene and protein expression in cancer cells for gene therapy. (I) Hybridization of antisense oligonucleotides (ASOs) to a targeting mRNA can result in specific inhibition of gene expression by the induction of RNase H endonuclease activity, which cleaves the mRNA-ASO heteroduplex. (II) Short interfering RNA (siRNA) is recognized by the RNA-induced silencing complex (RISC), guided by an antisense strand of the siRNA, specifically to bind and cleave targeting mRNA. (III) In vitro transcribed mRNA utilizes the protein synthesis machinery of host cells to translate the encoded genetic information into a protein. Ribosome subunits are recruited to mRNA with a cap and poly(A)-binding proteins, forming a translation initiation complex. (IV) In the clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) system, co-delivery of a single guide RNA (sgRNA) together with the mRNA encoding the Cas9 DNA endonuclease allows site-specific cleavage of dsDNA, leading to the knockout of a target gene and its product. Then, this will realize cancer therapy by RNA/Nucleic acid delivery

EVs are small membrane vesicles released into the extracellular matrix and they also play an important role in gene delivery and therapy in cancer [59]. Mutifunctional exosomes are derived from different cells types, including cancer cells, dendritic cells, B cells, T cells, mast cells and epithelial cells to deliver targeting genes for cancer therapy and tissue repair [63–66]. For example, HEK293 cells with advantages of high transfection and easy to gene operation are allowed for gene manipulation on exosomes. The biggest advantage of cancer cell-derived exosomes involved in gene delivery is targeting and low immunogenicity [263]. Zhou and collaborators have reported a novel mechanism that targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by mediating MALT1-NF-𝜅B-IL-6 axis of tumor-associated macrophages [264]. Ellipilli and collaborators have also reported GalNAc decorated exosomes as cargo for targeted delivery of Paclitaxel (PTX) and miR122 to liver tumors as an effective means to inhibit the hepatocellular carcinoma [265]. Because of the excellent performance, it has also been applied in cancer clinical trials. Researchers can consult related data on the database www.ClinicalTrials.gov (accessed in April, 2022) [266, 267]. However, some limitations are still remained for cancer-induced tissue repair, such as pharmacokinetic characteristics and potential safety issues [268–270].

Protein or peptide with unique sequences can demonstrate a variety of properties, including siRNA binding, membrane penetration, endosomal destruction, targeting, etc [271]. Cell-penetrating peptides (CPPS) are amphiphilic oligomers with positive-charge residues (arginine or lysine) and it is usually applied in gene delivery [272]. Deng and collaborators have reported a transdermal peptide, #PKU12. The antitumor effect of PKU12-based siRNA against HPV is perfect for human papillomavirus in vivo [273]. Protein or polypeptide delivery RNA strategies have high selectivity and activity in gene therapy and tissue repair.

Cancer-resected gene therapy for tissue repair

Fig. 9 Regulation of gene and protein expression using RNA/Nucleic acid in cancer therapy for tissue regeneration. (A) A schematic diagram of gene therapy in tissue repair after removing tumors. (B) A schematic diagram to depict the role of lnc030 in maintenance of BCSC stemness through regulating SQLE and cholesterol accumulation to stimulate PI3K/Akt signaling. (C) Intracellular cholesterol is measured in lnc030-knockdown (left) or SQLE-knockdown (right) Hs578T, BT549, MCF-7 derived spheres and their control spheres. (D) Tumor growth curve and tumor weight of each mouse group are measured. (B-D) Reproduced with permission [275]. Copyright 2020, Wiley. (E) Schematic illustration of therapeutic process of ADSC-loaded GO-GA-polymer scaffold with pH-triggered dual release of GO and GA. (F) The tumor growth curves after implantation of different formulations with and without NIR irradiation. (G) Histological analysis and histomorphometric measurements of adipose tissue regeneration in vivo. (E-G) Reproduced with permission [276]. Copyright 2019, Wiley. (H) A schematic diagram of nanocomposite multifunctional hydrogel for suppressing osteosarcoma recurrence and enhancing bone regeneration. Reproduced with permission [274]. Copyright 2022, Elsevier

As mentioned before, tissue defects after tumor surgery are difficult to repair [277]. For breast cancer patients, surgical removal of tumor tissue usually results in permanent breast defects, which brings great psychological pain to the patients [278]. Therefore, gene therapy plays an important role to induce post-cancer repair and tissue regeneration (Fig. 9A) [279]. Liu and collaborators report that a long non-coding RNA lnc030, cooperated with poly(rC) binding protein 2(PCBP2) to stabilize squalene epoxidase (SQLE) mRNA, resulting in an increase of cholesterol synthesis (Fig. 9B) [275]. The increased cholesterol also activates PI3K/Akt signaling and governs breast cancer stem cells stemness. Therefore, the lnc030-SQLE-cholesterol synthesis pathway is a therapeutic target for breast cancer treatment and adipose tissue regeneration (Fig. 9C, D) [275].

In addition, advanced functional scaffolds are also applied for cancer-resected tissue regeneration. Chen and collaborators fabricate a stimuli-responsive scaffold for breast cancer treatment and adipose tissue regeneration (Fig. 9E). This scaffold is composed of polyacrylic acid-g-polylactic acid (PAA-g-PLLA) modified graphene oxide (GO) with a cleavable bond in between (GO-PAA-g-PLLA), gambogic acid (GA), and polycaprolactone (PCL). These complex scaffolds can not only selectively induce the apoptosis of tumor cells, but also improve the capability to stimulate the differentiation of ADSCs into adipocytes (Fig. 9F, G) [276]. Chen and collaborators have also fabricated a composite scaffold of gelatin and Fe3O4 NPs for magnetic hyperthermia-based breast cancer treatment and adipose tissue regeneration. It can ablate breast cancer cell and facilitate the growth and adipogenesis of mesenchymal stem cells [280]. Currently, photothermal therapy is the commonly used method for most scaffolds for breast tumor treatment and adipose tissue regeneration [281]. If gene therapy is integrated into these scaffolds, better results will be achieved for adipose regeneration. The scaffolds with RNA lnc030 integration can realize breast cancer treatment and further contribute to the adipose tissue regeneration.

Similarly, bone tumor is clinically a malignant tumor and surgical resection is the common clinical treatment [282]. Although native bone tissue has the self-regeneration ability, inevitable damage to the bone is still unsettled [283, 284]. Therefore, gene therapy would be a preferable strategy to introduce targeting genes into cells for bone tumor treatment and bone tissue regeneration. Zhang and collaborators have fabricated a functional nanovector to deliver astrocyte elevated gene-1 (AEG-1) small interfering RNA (siRNA; siAEG-1) into osteosarcoma cells to silence the targeted gene both in vitro and in vivo. The results show that the Cs-g-PLLD-FA/siAEG-1 nanocomplexes could knockdown AEG-1 genes to inhibit the tumor cell proliferation, invasion and lung metastasis in tumor-bearing mice with low cytotoxicity and high efficacy [285]. Nasr-Esfahani and collaborators also prepare mesoporous bioactive glass (MBG) sub-micro particles to present the potential in treatment of osteosarcoma by releasing bioactive ions of Ca, Si and P, and contribute to bone regeneration by depositing hydroxylapatite (HA) [286]. Lai and collaborators demonstrate that multifunctional nanocomposite hydrogel has an excellent effect for suppressing osteosarcoma recurrence and enhancing bone regeneration (Fig. 9H) [274].

At present, many researchers have proposed the gene therapy method to treat bone tumor by preparing high-efficacy and low-toxicity vectors to discover novel long non-coding RNA, circular RNA or miRNA [287, 288]. Hu and collaborators have even mapped the single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma, which provides potential therapeutic targets for osteosarcoma [288]. Moreover, there are also many novel methods to treat bone tumor and contribute to bone regeneration by fabricating multifunctional scaffolds or vectors [274, 289, 290]. Combining gene therapy vectors and bioactive scaffolds, advanced biomaterials will provide a promising insight for synergetic tumor treatment and tissue regeneration (Table 5).

Table 5 Cancer-resected gene therapy for tissue repair

Therapeutic nucleic
acids	Delivery vectors	Therapeutic outcomes	Reference	
lnc030	poly(rC) binding protein 2(PCBP2)	A therapeutic target for breast cancer treatment and adipose tissue regeneration	[269]	
siAEG-1	Nanocomplexes	Knockdown AEG-1 genes to inhibit the tumor cell proliferation, invasion and lung metastasis in tumor-bearing mice with low cytotoxicity and high effiency	[280]	
branched-DNA	DNA-polyphenol nanocomplex	Showed specific targeting to tumor and achieved the best medical intervention effects	[291]	
branched-DNA/RNA	nanocomplex@A549m)	effectively delivered therapeutic siRNA to tumor sites and exhibited high RNAi efficiency and enhanced anti-tumor activity	[292]	
siRNA	siRNA/EGCG/protamine/HA	displayed the highest tumor inhibition effect and little toxicity to normal tissues

and organs

	[293]	
siRNA	MNC@LPMSA@siRNA@TA	siRNA was effectively delivered into the cytoplasmic region	[294]	
siEIF5A2	Mg(II)-Cat NPs	effectively accumulated in tumors and exerted significant antitumor

effects via inhibiting phosphoinositide 3-kinase/protein kinase B (P13K/Akt) signaling pathway

	[295]	
siRNA	siRNA-functionalized DBC-FeIII MPN	In PC3-Luc2 cells, 89% of the luciferase gene was silenced by siRNA-functionalized DBC-FeIII MPN nanoparticles	[296]	
siRNA	siRNA-functionalized DBC-FeIII MPN	89% of the luciferase gene was silenced by siRNA-functionalized DBC-FeIII MPN

nanoparticles

	[297]	
miRNA-21	Hydrogel&MIC@Antagomir-21	sustained release of Antagomir-21 and on-demand release of Cur	[298]	
dsRNA	NPPLL/EGCG/dsRNA	effectively protect dsRNA from double-stranded ribonuclease (dsRNase) degradation, increase the tolerance of dsRNA to dsRNase, enhance cellular uptake and endosome escape	[299]	

Conclusions and future perspectives

Tissue repair and regeneration are long-term concerns for postoperative patients, especially after orthopedics, neurology, and cancer operations. In order to alleviate the burden on patients and expedite recovery, regional gene therapy has been developed and is being considered as a potential approach for tissue regeneration and repair. Over the past two decades, regional gene therapy has been rapidly developed for tissue regeneration, and encompassing advances in vector types, delivery methods, as well as the design and fabrication of novel materials are also prosperous for efficient gene delivery and therapy in bone regeneration, cartilage regeneration, blood vessel regeneration, nerve regeneration and even cancer-resected tissue repair. Although gene therapy has shown the explosive development for tissue regeneration and repair, current mainstream programmes for regional gene therapy rely on viral-based vectors. Despite their inherent advantages such as extended duration and high payload capacity, there are still concerns about their safety, particularly in terms of immunogenicity. To completely overcome potential risks from viral and further improve gene delivery ability, various gene delivery biomaterials have been exploited for tissue regeneration and repair, including lipids, cationic polymers, peptides or proteins, dendritic/branched biomaterials, inorganic NPs and their composites. These novel gene carriers can not only enhance targeting accuracy and delivery ability to replace defective genes in damaged sites, but also emphasize the creation of new drugs and treatment procedures that are effective and less painful to eradicate all kinds of genetic tissue diseases. To date, gene therapy is still considered as the most potential solution to tissue regeneration and repair.

Improving the transfection efficiency, enhancing the transfection stability and reducing the toxicity are the common development direction of these biomaterials-based nonviral vectors for gene therapy and tissue regeneration. It is essential to further enhance the comprehension of the molecular mechanisms underlying tissue reconstruction and the effects of polymeric biomaterials on cell fate. Maximizing the transfection capacity of polymeric biomaterials in gene therapy remains a challenge, as currently, nonviral vectors are unable to achieve the same high transfection efficiency as viral vectors. In addition, although polymeric biomaterials offer desired release kinetics and spatially defined architectures, the optimal release time and the dose of therapeutic genes required for effective cartilage repair are still unknown. With the development of advanced biofabrication techniques, the combination of various biomaterials to construct composites with tailorable properties and spatially controlled biological function will be realized, and more personalized polymeric biomaterial-mediated gene delivery systems should be explored to promote clinical treatment effect. The precise regulation of each stage matching to the process of tissue formation is still hardly achieved at present. Therefore, advanced biomaterial-mediated gene delivery with efficient, well-defined and targeting transduction system will represent the next frontier to enhance tissue regeneration and repair in vivo.

Acknowledgements

This work was supported by National Natural Science Foundation of China (No. 82302401), Shanghai Overseas High-Level Talent Project and High-End Foreign Experts Introduction Plan (No. G2023013020L).

Author contributions

Conceptualization, W.Z. X.Z. and Y.W.; formal analysis, W.Z. and Y.W.; funding acquisition, Y.W.; methodology, all co-authors; project administration, Y.W.; resources, Y.W.; data curation, all co-authors; supervision, Y.W.; writing-original draft preparation, W.Z. and Y.W.; and writing-review and editing, all co-authors.

Funding

Open access funding provided by Shanghai University.

Data availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

The original online version of this article has been revised: the fig. 6 and 9 caption has been updated

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

8/29/2024

A Correction to this paper has been published: 10.1186/s12951-024-02769-x
==== Refs
References

1. Zhang Z Native tissue-based strategies for meniscus repair and regeneration Cell Tissue Res 2018 373 337 50 10.1007/s00441-017-2778-6 29397425
Zhang Z, et al. Native tissue-based strategies for meniscus repair and regeneration. Cell Tissue Res. 2018;373:337–50.29397425 10.1007/s00441-017-2778-6
2. Salhotra A Mechanisms of bone development and repair Nat Rev Mol Cell Biol 2020 21 696 711 10.1038/s41580-020-00279-w 32901139
Salhotra A, et al. Mechanisms of bone development and repair. Nat Rev Mol Cell Biol. 2020;21:696–711.32901139 10.1038/s41580-020-00279-w
3. Tzahor E Poss KD Cardiac regeneration strategies: staying young at heart Science 2017 356 1035 9 10.1126/science.aam5894 28596337
Tzahor E, Poss KD. Cardiac regeneration strategies: staying young at heart. Science. 2017;356:1035–9.28596337 10.1126/science.aam5894
4. Rana D Development of decellularized scaffolds for stem cell-driven tissue engineering J Tissue Eng Regen Med 2017 11 942 65 10.1002/term.2061 26119160
Rana D, et al. Development of decellularized scaffolds for stem cell-driven tissue engineering. J Tissue Eng Regen Med. 2017;11:942–65.26119160 10.1002/term.2061
5. Nerem RM Tissue engineering in the USA Med Biol Eng Comput 1992 30 CE8 12 10.1007/BF02446171 1487936
Nerem RM, et al. Tissue engineering in the USA. Med Biol Eng Comput. 1992;30:CE8–12.1487936 10.1007/BF02446171
6. Khademhosseini A A decade of progress in tissue engineering Nat Protoc 2016 11 1775 81 10.1038/nprot.2016.123 27583639
Khademhosseini A, et al. A decade of progress in tissue engineering. Nat Protoc. 2016;11:1775–81.27583639 10.1038/nprot.2016.123
7. Berthiaume F Tissue engineering and regenerative medicine: history, progress, and challenges Annu Rev Chem Biomol Eng 2011 2 403 30 10.1146/annurev-chembioeng-061010-114257 22432625
Berthiaume F, et al. Tissue engineering and regenerative medicine: history, progress, and challenges. Annu Rev Chem Biomol Eng. 2011;2:403–30.22432625 10.1146/annurev-chembioeng-061010-114257
8. Griffith LG Tissue engineering–current challenges and expanding opportunities Science 2002 295 1009 14 10.1126/science.1069210 11834815
Griffith LG, et al. Tissue engineering–current challenges and expanding opportunities. Science. 2002;295:1009–14.11834815 10.1126/science.1069210
9. Hassanzadeh P Tissue engineering: still facing a long way ahead J Control Release 2018 279 181 97 10.1016/j.jconrel.2018.04.024 29655988
Hassanzadeh P, et al. Tissue engineering: still facing a long way ahead. J Control Release. 2018;279:181–97.29655988 10.1016/j.jconrel.2018.04.024
10. Xia H Tissue repair and regeneration with endogenous stem cells Nat Rev Mater 2018 3 174 93 10.1038/s41578-018-0027-6
Xia H, et al. Tissue repair and regeneration with endogenous stem cells. Nat Rev Mater. 2018;3:174–93.10.1038/s41578-018-0027-6
11. Ferrari S Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy Cell Stem Cell 2023 30 549 70 10.1016/j.stem.2023.04.014 37146580
Ferrari S, et al. Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy. Cell Stem Cell. 2023;30:549–70.37146580 10.1016/j.stem.2023.04.014
12. Fox T Access to gene therapy for rare diseases when commercialization is not fit for purpose Nat Med 2023 29 518 9 10.1038/s41591-023-02208-8 36782029
Fox T, et al. Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat Med. 2023;29:518–9.36782029 10.1038/s41591-023-02208-8
13. Birch SM Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy Sci Transl Med 2023 15 eabo1815 10.1126/scitranslmed.abo1815 36599002
Birch SM, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med. 2023;15:eabo1815.36599002 10.1126/scitranslmed.abo1815
14. Kaczmarek JC Advances in the delivery of RNA therapeutics: from concept to clinical reality Genome Med 2017 9 60 10.1186/s13073-017-0450-0 28655327
Kaczmarek JC, et al. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9:60.28655327 10.1186/s13073-017-0450-0
15. Wang Y Is viral vector gene delivery more effective using biomaterials? Adv Healthc Mater 2021 10 2001238 10.1002/adhm.202001238
Wang Y, et al. Is viral vector gene delivery more effective using biomaterials? Adv Healthc Mater. 2021;10:2001238.10.1002/adhm.202001238
16. Yin H Non-viral vectors for gene-based therapy Nat Rev Genet 2014 15 541 55 10.1038/nrg3763 25022906
Yin H, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541–55.25022906 10.1038/nrg3763
17. Gao K Nonviral methods for siRNA delivery Mol Pharm 2009 6 651 8 10.1021/mp800134q 19115957
Gao K, et al. Nonviral methods for siRNA delivery. Mol Pharm. 2009;6:651–8.19115957 10.1021/mp800134q
18. Finer M A brief account of viral vectors and their promise for gene therapy Gene Ther 2017 24 1 2 10.1038/gt.2016.71 28123184
Finer M, et al. A brief account of viral vectors and their promise for gene therapy. Gene Ther. 2017;24:1–2.28123184 10.1038/gt.2016.71
19. Chien Y-H Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial Lancet Child Adolesc 2017 1 265 73 10.1016/S2352-4642(17)30125-6
Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu SI, Byrne BJ, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. Lancet Child Adolesc. 2017;1:265–73.10.1016/S2352-4642(17)30125-6
20. Fischer MD Efficacy and safety of Retinal Gene Therapy using Adeno-Associated Virus Vector for patients with choroideremia: a Randomized Clinical Trial JAMA Ophthalmol 2019 137 1247 54 10.1001/jamaophthalmol.2019.3278 31465092
Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial. JAMA Ophthalmol. 2019;137:1247–54.31465092 10.1001/jamaophthalmol.2019.3278
21. Chen S-H Recombinant viral vectors as neuroscience tools Curr Protoc Neurosci 2019 87 e67 10.1002/cpns.67 30901512
Chen S-H, et al. Recombinant viral vectors as neuroscience tools. Curr Protoc Neurosci. 2019;87:e67.30901512 10.1002/cpns.67
22. Choi J-H Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons Mol Brain 2014 7 17 10.1186/1756-6606-7-17 24618276
Choi J-H, et al. Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol Brain. 2014;7:17.24618276 10.1186/1756-6606-7-17
23. Davidson BL Viral vectors for gene delivery to the nervous system Nat Rev Neurosci 2003 4 353 64 10.1038/nrn1104 12728263
Davidson BL, et al. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci. 2003;4:353–64.12728263 10.1038/nrn1104
24. Flotte TR Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors Gene Ther 2004 11 805 10 10.1038/sj.gt.3302233 15042119
Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2004;11:805–10.15042119 10.1038/sj.gt.3302233
25. Wang Y Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery Br J Cancer 2005 92 1414 20 10.1038/sj.bjc.6602494 15812558
Wang Y, et al. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery. Br J Cancer. 2005;92:1414–20.15812558 10.1038/sj.bjc.6602494
26. Lagan A, Shasha D, Croce CM. Synthetic RNAs for gene regulation: design principles and computational tools. Front Bioeng Biotechnol. 2014;2:65.
27. Buck J Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery ACS Nano 2019 13 3754 82 10.1021/acsnano.8b07858 30908008
Buck J, et al. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery. ACS Nano. 2019;13:3754–82.30908008 10.1021/acsnano.8b07858
28. Anderson DG Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery Angew Chem Int Ed 2003 42 3153 8 10.1002/anie.200351244
Anderson DG, et al. Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed. 2003;42:3153–8.10.1002/anie.200351244
29. Yan H Nucleic acid nanotechnology Science 2004 306 2048 9 10.1126/science.1106754 15604395
Yan H. Nucleic acid nanotechnology. Science. 2004;306:2048–9.15604395 10.1126/science.1106754
30. Kinard LA Bone morphogenetic protein-2 release from composite hydrogels of oligo(poly(ethylene glycol) fumarate) and gelatin Pharm Res 2013 30 2332 43 10.1007/s11095-013-1077-5 23686376
Kinard LA, et al. Bone morphogenetic protein-2 release from composite hydrogels of oligo(poly(ethylene glycol) fumarate) and gelatin. Pharm Res. 2013;30:2332–43.23686376 10.1007/s11095-013-1077-5
31. Elangovan S The enhancement of bone regeneration by gene activated matrix encoding for platelet derived growth factor Biomaterials 2014 35 737 47 10.1016/j.biomaterials.2013.10.021 24161167
Elangovan S, et al. The enhancement of bone regeneration by gene activated matrix encoding for platelet derived growth factor. Biomaterials. 2014;35:737–47.24161167 10.1016/j.biomaterials.2013.10.021
32. Odabas S, Feichtinger GA, Korkusuz P, Inci I, Bilgic E, Yar AS, et al. Auricular cartilage repair using cryogel scaffolds loaded with BMP-7-expressing primary chondrocytes. J Tissue Eng Regen Med. 2013;7(10):831–40.
33. El-Aneed Current strategies in cancer gene therapy Eur J Pharmacol 2004 498 1 8 10.1016/j.ejphar.2004.06.054 15363969
El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol. 2004;498:1–8.15363969 10.1016/j.ejphar.2004.06.054
34. Hanz S Integration of retrograde axonal and nuclear transport mechanisms in neurons: implications for therapeutics Neuroscientist 2004 10 404 8 10.1177/1073858404267884 15359007
Hanz S, et al. Integration of retrograde axonal and nuclear transport mechanisms in neurons: implications for therapeutics. Neuroscientist. 2004;10:404–8.15359007 10.1177/1073858404267884
35. Zielińska A Scaffolds for drug delivery and tissue engineering: the role of genetics JOCR 2023 359 207 23
Zielińska A, et al. Scaffolds for drug delivery and tissue engineering: the role of genetics. JOCR. 2023;359:207–23.
36. Mulligan RC The basic science of gene therapy Science 1993 260 926 32 10.1126/science.8493530 8493530
Mulligan RC. The basic science of gene therapy. Science. 1993;260:926–32.8493530 10.1126/science.8493530
37. Petit C, Bonnet C, Safieddine S. Deafness: from genetic architecture to gene therapy. Nat Rev Genet. 2023;24:665–86.
38. Dunbar CE Gene therapy comes of age Science 2018 359 eaan4672 10.1126/science.aan4672 29326244
Dunbar CE, et al. Gene therapy comes of age. Science. 2018;359:eaan4672.29326244 10.1126/science.aan4672
39. Juengst ET The NIH points to consider and the limits of human gene therapy Hum Gene Ther 1990 1 425 33 10.1089/hum.1990.1.4-425 2078585
Juengst ET. The NIH points to consider and the limits of human gene therapy. Hum Gene Ther. 1990;1:425–33.2078585 10.1089/hum.1990.1.4-425
40. Naldini L Gene therapy returns to centre stage Nature 2015 526 351 60 10.1038/nature15818 26469046
Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–60.26469046 10.1038/nature15818
41. van Overbeeke E Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions Drug Discov Today 2021 26 399 415 10.1016/j.drudis.2020.11.024 33242695
van Overbeeke E, et al. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today. 2021;26:399–415.33242695 10.1016/j.drudis.2020.11.024
42. Shukla V The landscape of cellular and gene therapy products: authorization, discontinuations, and cost Hum Gene Ther Clin Dev 2019 30 102 13 10.1089/humc.2018.201 30968714
Shukla V, et al. The landscape of cellular and gene therapy products: authorization, discontinuations, and cost. Hum Gene Ther Clin Dev. 2019;30:102–13.30968714 10.1089/humc.2018.201
43. Somia N Gene therapy: trials and tribulations Nat Rev Genet 2000 1 91 9 10.1038/35038533 11253666
Somia N, et al. Gene therapy: trials and tribulations. Nat Rev Genet. 2000;1:91–9.11253666 10.1038/35038533
44. Ginn SL Gene therapy clinical trials worldwide to 2017: an update J Gene Med 2018 20 e3015 10.1002/jgm.3015 29575374
Ginn SL, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20:e3015.29575374 10.1002/jgm.3015
45. Wanisch K Integration-deficient lentiviral vectors: a slow coming of age Mol Ther 2009 17 1316 32 10.1038/mt.2009.122 19491821
Wanisch K, et al. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther. 2009;17:1316–32.19491821 10.1038/mt.2009.122
46. Bleiziffer O Gene transfer strategies in tissue engineering J Cell Mol Med 2007 11 206 23 10.1111/j.1582-4934.2007.00027.x 17488473
Bleiziffer O, et al. Gene transfer strategies in tissue engineering. J Cell Mol Med. 2007;11:206–23.17488473 10.1111/j.1582-4934.2007.00027.x
47. Rizk M Patisiran for the treatment of patients with familial amyloid polyneuropathy Drugs Today 2019 55 315 27 10.1358/dot.2019.55.5.2958475
Rizk M, et al. Patisiran for the treatment of patients with familial amyloid polyneuropathy. Drugs Today. 2019;55:315–27.10.1358/dot.2019.55.5.2958475
48. Baden LR Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med 2021 384 403 16 10.1056/NEJMoa2035389 33378609
Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.33378609 10.1056/NEJMoa2035389
49. Polack FP Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med 2020 383 2603 15 10.1056/NEJMoa2034577 33301246
Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.33301246 10.1056/NEJMoa2034577
50. Rojas LA Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Nature 2023 618 144 50 10.1038/s41586-023-06063-y 37165196
Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144–50.37165196 10.1038/s41586-023-06063-y
51. Zuckerman JE Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA PNAS 2014 111 11449 54 10.1073/pnas.1411393111 25049380
Zuckerman JE, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. PNAS. 2014;111:11449–54.25049380 10.1073/pnas.1411393111
52. Han X Biomaterial-assisted biotherapy: a brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy Bioact Mater 2022 17 29 48 35386442
Han X, et al. Biomaterial-assisted biotherapy: a brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy. Bioact Mater. 2022;17:29–48.35386442
53. Han S-o Development of biomaterials for gene therapy Mol Ther 2000 2 302 17 10.1006/mthe.2000.0142 11020345
Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000;2:302–17.11020345 10.1006/mthe.2000.0142
54. Wong SY Polymer systems for gene delivery—past, present, and future Prog Polym Sci 2007 32 799 837 10.1016/j.progpolymsci.2007.05.007
Wong SY, et al. Polymer systems for gene delivery—past, present, and future. Prog Polym Sci. 2007;32:799–837.10.1016/j.progpolymsci.2007.05.007
55. Dobson J Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery Gene Ther 2006 13 283 7 10.1038/sj.gt.3302720 16462855
Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 2006;13:283–7.16462855 10.1038/sj.gt.3302720
56. Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27.
57. Lostalé-Seijo I Synthetic materials at the forefront of gene delivery Nat Rev Chem 2018 2 258 77 10.1038/s41570-018-0039-1
Lostalé-Seijo I, et al. Synthetic materials at the forefront of gene delivery. Nat Rev Chem. 2018;2:258–77.10.1038/s41570-018-0039-1
58. Sano A Atelocollagen for protein and gene delivery Adv Drug Deliv Rev 2003 55 1651 77 10.1016/j.addr.2003.08.005 14623406
Sano A, et al. Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev. 2003;55:1651–77.14623406 10.1016/j.addr.2003.08.005
59. Cecchin R, Troyer Z, Witwer k, Morris KV. Extracellular vesicles: the next generation in gene therapy delivery. Mol Ther. 2023;31:1225–30.
60. Angela Barba A Novel lipid and polymeric materials as delivery systems for nucleic acid based drugs Curr Drug Metab 2015 16 427 52 10.2174/1389200216666150812142557 26264345
Angela Barba A, et al. Novel lipid and polymeric materials as delivery systems for nucleic acid based drugs. Curr Drug Metab. 2015;16:427–52.26264345 10.2174/1389200216666150812142557
61. Vader P Extracellular vesicles for drug delivery Adv Drug Deliv Rev 2016 106 148 56 10.1016/j.addr.2016.02.006 26928656
Vader P, et al. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106:148–56.26928656 10.1016/j.addr.2016.02.006
62. Elsharkasy OM Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev 2020 159 332 43 10.1016/j.addr.2020.04.004 32305351
Elsharkasy OM, et al. Extracellular vesicles as drug delivery systems: why and how? Adv Drug Deliv Rev. 2020;159:332–43.32305351 10.1016/j.addr.2020.04.004
63. Tan A Exosomes as nano-theranostic delivery platforms for gene therapy Adv Drug Deliv Rev 2013 65 357 67 10.1016/j.addr.2012.06.014 22820532
Tan A, et al. Exosomes as nano-theranostic delivery platforms for gene therapy. Adv Drug Deliv Rev. 2013;65:357–67.22820532 10.1016/j.addr.2012.06.014
64. Azmi AS Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review Cancer Metastasis Rev 2013 32 623 42 10.1007/s10555-013-9441-9 23709120
Azmi AS, et al. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013;32:623–42.23709120 10.1007/s10555-013-9441-9
65. Vlassov AV Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials Biochim Biophys Acta Gen Subj 2012 1820 940 8 10.1016/j.bbagen.2012.03.017
Vlassov AV, et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta Gen Subj. 2012;1820:940–8.10.1016/j.bbagen.2012.03.017
66. Mathivanan S Exosomes: extracellular organelles important in intercellular communication J Proteom 2010 73 1907 20 10.1016/j.jprot.2010.06.006
Mathivanan S, et al. Exosomes: extracellular organelles important in intercellular communication. J Proteom. 2010;73:1907–20.10.1016/j.jprot.2010.06.006
67. Hudry E Exosome-associated AAV vector as a robust and convenient neuroscience tool Gene Ther 2016 23 380 92 10.1038/gt.2016.11 26836117
Hudry E, et al. Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther. 2016;23:380–92.26836117 10.1038/gt.2016.11
68. Ahmadi SE Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy Cancer Gene Ther 2023 30 936 54 10.1038/s41417-023-00597-z 36854897
Ahmadi SE, et al. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy. Cancer Gene Ther. 2023;30:936–54.36854897 10.1038/s41417-023-00597-z
69. Alvarez-Erviti L Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 2011 29 341 5 10.1038/nbt.1807 21423189
Alvarez-Erviti L, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–5.21423189 10.1038/nbt.1807
70. Munagala R Exosome-mediated delivery of RNA and DNA for gene therapy Cancer Lett 2021 505 58 72 10.1016/j.canlet.2021.02.011 33610731
Munagala R, et al. Exosome-mediated delivery of RNA and DNA for gene therapy. Cancer Lett. 2021;505:58–72.33610731 10.1016/j.canlet.2021.02.011
71. Gong L CD44-targeting drug delivery system of exosomes loading forsythiaside a combats liver fibrosis via regulating NLRP3‐mediated pyroptosis Adv Healthc Mater 2023 12 2202228 10.1002/adhm.202202228
Gong L, et al. CD44-targeting drug delivery system of exosomes loading forsythiaside a combats liver fibrosis via regulating NLRP3‐mediated pyroptosis. Adv Healthc Mater. 2023;12:2202228.10.1002/adhm.202202228
72. Duan L Exosome-mediated delivery of gene vectors for gene therapy Nanoscale 2021 13 1387 97 10.1039/D0NR07622H 33350419
Duan L, et al. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale. 2021;13:1387–97.33350419 10.1039/D0NR07622H
73. Liang Y Chondrocyte-targeted MicroRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy ACS Appl Mater Interfaces 2020 12 36938 47 10.1021/acsami.0c10458 32814390
Liang Y, Xu X, Li X, Xiong J, Li B, Duan L, et al. Chondrocyte-targeted MicroRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy. ACS Appl Mater Interfaces. 2020;12:36938–47.32814390 10.1021/acsami.0c10458
74. Gori JL Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy Hum Gene Ther 2015 26 443 51 10.1089/hum.2015.074 26068008
Gori JL, Hsu PD, Maeder ML, Shen S, Welstead GG, Bumcrot D. Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy. Hum Gene Ther. 2015;26:443–51.26068008 10.1089/hum.2015.074
75. Kim SM Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting J Control Release 2017 266 8 16 10.1016/j.jconrel.2017.09.013 28916446
Kim SM, et al. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017;266:8–16.28916446 10.1016/j.jconrel.2017.09.013
76. Kallenbach NR An immobile nucleic acid junction constructed from oligonucleotides Nature 1983 305 829 31 10.1038/305829a0
Kallenbach NR, Rong-Ine Ma, Seeman NC. An immobile nucleic acid junction constructed from oligonucleotides. Nature. 1983;305:829–31.10.1038/305829a0
77. Rothemund PWK Folding DNA to create nanoscale shapes and patterns Nature 2006 440 297 302 10.1038/nature04586 16541064
Rothemund PWK. Folding DNA to create nanoscale shapes and patterns. Nature. 2006;440:297–302.16541064 10.1038/nature04586
78. Chen J Synthesis from DNA of a molecule with the connectivity of a cube Nature 1991 350 631 3 10.1038/350631a0 2017259
Chen J, et al. Synthesis from DNA of a molecule with the connectivity of a cube. Nature. 1991;350:631–3.2017259 10.1038/350631a0
79. Andersen ES Self-assembly of a nanoscale DNA box with a controllable lid Nature 2009 459 73 6 10.1038/nature07971 19424153
Andersen ES, et al. Self-assembly of a nanoscale DNA box with a controllable lid. Nature. 2009;459:73–6.19424153 10.1038/nature07971
80. Zadegan RM Construction of a 4 zeptoliters switchable 3D DNA box origami ACS Nano 2012 6 10050 3 10.1021/nn303767b 23030709
Zadegan RM, et al. Construction of a 4 zeptoliters switchable 3D DNA box origami. ACS Nano. 2012;6:10050–3.23030709 10.1021/nn303767b
81. Li S-d Nonviral gene therapy: promises and challenges Gene Ther 2000 7 31 4 10.1038/sj.gt.3301110 10680013
Li SD, Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. 2000;7:31–4.10680013 10.1038/sj.gt.3301110
82. Albertsen CH The role of lipid components in lipid nanoparticles for vaccines and gene therapy Adv Drug Deliv Rev 2022 188 114416 10.1016/j.addr.2022.114416 35787388
Albertsen CH, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.35787388 10.1016/j.addr.2022.114416
83. Cullis PR Lipid nanoparticle systems for enabling gene therapies Mol Ther 2017 25 1467 75 10.1016/j.ymthe.2017.03.013 28412170
Cullis PR, et al. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25:1467–75.28412170 10.1016/j.ymthe.2017.03.013
84. del Pozo-Rodriguez A Applications of lipid nanoparticles in gene therapy Eur J Pharm Biopharm 2016 109 184 93 10.1016/j.ejpb.2016.10.016 27789356
del Pozo-Rodriguez A, et al. Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 2016;109:184–93.27789356 10.1016/j.ejpb.2016.10.016
85. Dalby B Advanced transfection with lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications Methods 2004 33 95 103 10.1016/j.ymeth.2003.11.023 15121163
Dalby B, et al. Advanced transfection with lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods. 2004;33:95–103.15121163 10.1016/j.ymeth.2003.11.023
86. Kulkarni JA Lipid nanoparticles enabling gene therapies: from concepts to clinical utility Nucleic Acid Ther 2018 28 146 57 10.1089/nat.2018.0721 29683383
Kulkarni JA, et al. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28:146–57.29683383 10.1089/nat.2018.0721
87. Li L Multifunctional nucleus-targeting nanoparticles with ultra-high gene transfection efficiency for in vivo gene therapy Theranostics 2017 7 1633 10.7150/thno.17588 28529641
Li L, et al. Multifunctional nucleus-targeting nanoparticles with ultra-high gene transfection efficiency for in vivo gene therapy. Theranostics. 2017;7:1633.28529641 10.7150/thno.17588
88. Williams DJ, Puhl HL, Ikeda SR. A simple, highly efficient method for heterologous expression in mammalian primary neurons using cationic lipid-mediated mRNA transfection. Front Neurosci. 2010;4:181.
89. Tönges L Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons RNA 2006 12 1431 8 10.1261/rna.2252206 16699166
Tönges L, et al. Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA. 2006;12:1431–8.16699166 10.1261/rna.2252206
90. Kranz LM Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy Nature 2016 534 396 401 10.1038/nature18300 27281205
Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401.27281205 10.1038/nature18300
91. Rajala A Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo Nano Lett 2014 14 5257 63 10.1021/nl502275s 25115433
Rajala A, et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 2014;14:5257–63.25115433 10.1021/nl502275s
92. Li M Composition design and medical application of liposomes Eur J Med Chem 2019 164 640 53 10.1016/j.ejmech.2019.01.007 30640028
Li M, et al. Composition design and medical application of liposomes. Eur J Med Chem. 2019;164:640–53.30640028 10.1016/j.ejmech.2019.01.007
93. De Smedt SC Cationic polymer based gene delivery systems Pharm Res 2000 17 113 26 10.1023/A:1007548826495 10751024
De Smedt SC, et al. Cationic polymer based gene delivery systems. Pharm Res. 2000;17:113–26.10751024 10.1023/A:1007548826495
94. Zhang S Cationic compounds used in lipoplexes and polyplexes for gene delivery J Control Release 2004 100 165 80 10.1016/j.jconrel.2004.08.019 15544865
Zhang S, et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release. 2004;100:165–80.15544865 10.1016/j.jconrel.2004.08.019
95. Chen H, Guo L, Ding J, Zhou W, Qi Y. A general and efficient strategy for gene delivery based on tea polyphenols intercalation and self-polymerization. Adv Sci. 2023:2302620.
96. Zhou Z Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration Adv Drug Deliv Rev 2017 115 115 54 10.1016/j.addr.2017.07.021 28778715
Zhou Z, et al. Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv Drug Deliv Rev. 2017;115:115–54.28778715 10.1016/j.addr.2017.07.021
97. Zeng M Efficient and robust highly branched poly (β-amino ester)/minicircle COL7A1 polymeric nanoparticles for gene delivery to recessive dystrophic epidermolysis bullosa keratinocytes ACS Appl Mater Interfaces 2019 11 30661 72 10.1021/acsami.9b13135 31390173
Zeng M, et al. Efficient and robust highly branched poly (β-amino ester)/minicircle COL7A1 polymeric nanoparticles for gene delivery to recessive dystrophic epidermolysis bullosa keratinocytes. ACS Appl Mater Interfaces. 2019;11:30661–72.31390173 10.1021/acsami.9b13135
98. Borchard G Chitosans for gene delivery Adv Drug Deliv Rev 2001 52 145 50 10.1016/S0169-409X(01)00198-3 11718938
Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev. 2001;52:145–50.11718938 10.1016/S0169-409X(01)00198-3
99. Boussif O A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine PNAS 1995 92 7297 301 10.1073/pnas.92.16.7297 7638184
Boussif O, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. PNAS. 1995;92:7297–301.7638184 10.1073/pnas.92.16.7297
100. Jäger M Branched and linear poly (ethylene imine)-based conjugates: synthetic modification, characterization, and application Chem Soc Rev 2012 41 4755 67 10.1039/c2cs35146c 22648524
Jäger M, et al. Branched and linear poly (ethylene imine)-based conjugates: synthetic modification, characterization, and application. Chem Soc Rev. 2012;41:4755–67.22648524 10.1039/c2cs35146c
101. Qin L Gold nanorod-assembled ZnGa 2 O 4: cr nanofibers for LED-amplified gene silencing in cancer cells Nanoscale 2018 10 13432 42 10.1039/C8NR03802C 29972189
Qin L, et al. Gold nanorod-assembled ZnGa 2 O 4: cr nanofibers for LED-amplified gene silencing in cancer cells. Nanoscale. 2018;10:13432–42.29972189 10.1039/C8NR03802C
102. Laroui H Fab’-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis J Control Release 2014 186 41 53 10.1016/j.jconrel.2014.04.046 24810114
Laroui H, et al. Fab’-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release. 2014;186:41–53.24810114 10.1016/j.jconrel.2014.04.046
103. Tian Y Polyvinylamine with moderate binding affinity as a highly effective vehicle for RNA delivery J Control Release 2022 345 20 37 10.1016/j.jconrel.2022.03.003 35248648
Tian Y, et al. Polyvinylamine with moderate binding affinity as a highly effective vehicle for RNA delivery. J Control Release. 2022;345:20–37.35248648 10.1016/j.jconrel.2022.03.003
104. Godbey W Poly (ethylenimine) and its role in gene delivery J Control Release 1999 60 149 60 10.1016/S0168-3659(99)00090-5 10425321
Godbey W, et al. Poly (ethylenimine) and its role in gene delivery. J Control Release. 1999;60:149–60.10425321 10.1016/S0168-3659(99)00090-5
105. Kievit FM PEI–PEG–chitosan-copolymer‐coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection Adv Funct Mater 2009 19 2244 51 10.1002/adfm.200801844 20160995
Kievit FM, et al. PEI–PEG–chitosan-copolymer‐coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater. 2009;19:2244–51.20160995 10.1002/adfm.200801844
106. Rohiwal SS Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing Sci Rep 2020 10 4619 10.1038/s41598-020-61465-6 32165679
Rohiwal SS, et al. Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing. Sci Rep. 2020;10:4619.32165679 10.1038/s41598-020-61465-6
107. Casper J Core–shell structured chitosan-polyethylenimine nanoparticles for gene delivery: improved stability, cellular uptake, and transfection efficiency Macromol Biosci 2023 23 2200314 10.1002/mabi.202200314
Casper J, et al. Core–shell structured chitosan-polyethylenimine nanoparticles for gene delivery: improved stability, cellular uptake, and transfection efficiency. Macromol Biosci. 2023;23:2200314.10.1002/mabi.202200314
108. Romani C Selectively fluorinated PAMAM–arginine conjugates as gene delivery vectors Bioconjug Chem 2023 34 1084 95 10.1021/acs.bioconjchem.3c00139 37221455
Romani C, et al. Selectively fluorinated PAMAM–arginine conjugates as gene delivery vectors. Bioconjug Chem. 2023;34:1084–95.37221455 10.1021/acs.bioconjchem.3c00139
109. Huang HC Inorganic nanoparticles for cancer imaging and therapy J Control Release 2011 155 344 57 10.1016/j.jconrel.2011.06.004 21723891
Huang HC, et al. Inorganic nanoparticles for cancer imaging and therapy. J Control Release. 2011;155:344–57.21723891 10.1016/j.jconrel.2011.06.004
110. Mitchell MJ Engineering precision nanoparticles for drug delivery Nat Rev Drug Discov 2021 20 101 24 10.1038/s41573-020-0090-8 33277608
Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101–24.33277608 10.1038/s41573-020-0090-8
111. Cutler JI Spherical nucleic acids J Am Chem Soc 2012 134 1376 91 10.1021/ja209351u 22229439
Cutler JI, et al. Spherical nucleic acids. J Am Chem Soc. 2012;134:1376–91.22229439 10.1021/ja209351u
112. Conde J Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells Adv Funct Mater 2015 25 4183 94 10.1002/adfm.201501283 27340392
Conde J, et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells. Adv Funct Mater. 2015;25:4183–94.27340392 10.1002/adfm.201501283
113. Conde J Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance PNAS 2015 112 E1278 1287 10.1073/pnas.1421229112 25733851
Conde J, et al. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. PNAS. 2015;112:E1278–1287.25733851 10.1073/pnas.1421229112
114. Gilam A Local microRNA delivery targets Palladin and prevents metastatic breast cancer Nat Commun 2016 7 12868 10.1038/ncomms12868 27641360
Gilam A, et al. Local microRNA delivery targets Palladin and prevents metastatic breast cancer. Nat Commun. 2016;7:12868.27641360 10.1038/ncomms12868
115. Dai X Controlled synthesis and surface engineering of janus chitosan-gold nanoparticles for photoacoustic imaging-guided synergistic gene/photothermal therapy Small 2021 17 e2006004 10.1002/smll.202006004 33619841
Dai X, et al. Controlled synthesis and surface engineering of janus chitosan-gold nanoparticles for photoacoustic imaging-guided synergistic gene/photothermal therapy. Small. 2021;17:e2006004.33619841 10.1002/smll.202006004
116. Luther DC Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles Adv Drug Deliv Rev 2020 156 188 213 10.1016/j.addr.2020.06.020 32610061
Luther DC, et al. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev. 2020;156:188–213.32610061 10.1016/j.addr.2020.06.020
117. Zhou Y Mesoporous silica nanoparticles for drug and gene delivery Acta Pharm Sin B 2018 8 165 77 10.1016/j.apsb.2018.01.007 29719777
Zhou Y, et al. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B. 2018;8:165–77.29719777 10.1016/j.apsb.2018.01.007
118. Hussein HA,Nazir MS, Azra N, Qamar Z, Seeni A, Tengku Din TADA, Abdullah MA. Novel drug and gene delivery system and imaging agent based on marine diatom biosilica nanoparticles. Mar Drugs 2022;20(8):480.
119. Huang XQ Hollow mesoporous zirconia delivery system for biomineralization precursors Acta Biomater 2018 67 366 77 10.1016/j.actbio.2017.11.049 29208555
Huang XQ, et al. Hollow mesoporous zirconia delivery system for biomineralization precursors. Acta Biomater. 2018;67:366–77.29208555 10.1016/j.actbio.2017.11.049
120. Rasool N Thiol-functionalized, antioxidant, and osteogenic mesoporous silica nanoparticles for osteoporosis ACS Biomater Sci Eng 2023 9 3535 45 10.1021/acsbiomaterials.3c00479 37172017
Rasool N, et al. Thiol-functionalized, antioxidant, and osteogenic mesoporous silica nanoparticles for osteoporosis. ACS Biomater Sci Eng. 2023;9:3535–45.37172017 10.1021/acsbiomaterials.3c00479
121. Mohammadpour R Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications Adv Drug Deliv Rev 2019 144 112 32 10.1016/j.addr.2019.07.006 31295521
Mohammadpour R, et al. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev. 2019;144:112–32.31295521 10.1016/j.addr.2019.07.006
122. Arami H In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles Chem Soc Rev 2015 44 8576 607 10.1039/C5CS00541H 26390044
Arami H, et al. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015;44:8576–607.26390044 10.1039/C5CS00541H
123. Nam SH Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides Arch Pharm Res 2023 46 18 34 10.1007/s12272-022-01425-y 36593377
Nam SH, et al. Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides. Arch Pharm Res. 2023;46:18–34.36593377 10.1007/s12272-022-01425-y
124. Snyder EL Cell penetrating peptides in drug delivery Pharm Res 2004 21 389 93 10.1023/B:PHAM.0000019289.61978.f5 15070086
Snyder EL, et al. Cell penetrating peptides in drug delivery. Pharm Res. 2004;21:389–93.15070086 10.1023/B:PHAM.0000019289.61978.f5
125. Wu H Cell-penetrating peptide: a powerful delivery tool for DNA-free crop genome editing Plant Sci 2022 324 111436 10.1016/j.plantsci.2022.111436 36037982
Wu H, et al. Cell-penetrating peptide: a powerful delivery tool for DNA-free crop genome editing. Plant Sci. 2022;324:111436.36037982 10.1016/j.plantsci.2022.111436
126. Wang Y Overcoming the blood-brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules Adv Mater 2023 35 e2208018 10.1002/adma.202208018 36445243
Wang Y, et al. Overcoming the blood-brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules. Adv Mater. 2023;35:e2208018.36445243 10.1002/adma.202208018
127. Cutroneo KR Gene therapy for tissue regeneration J Cell Biochem 2003 88 418 25 10.1002/jcb.10357 12520545
Cutroneo KR. Gene therapy for tissue regeneration. J Cell Biochem. 2003;88:418–25.12520545 10.1002/jcb.10357
128. Goldman JA Gene regulatory programmes of tissue regeneration Nat Rev Genet 2020 21 511 25 10.1038/s41576-020-0239-7 32504079
Goldman JA, et al. Gene regulatory programmes of tissue regeneration. Nat Rev Genet. 2020;21:511–25.32504079 10.1038/s41576-020-0239-7
129. Kusano KF Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling Nat Med 2005 11 1197 204 10.1038/nm1313 16244652
Kusano KF, et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med. 2005;11:1197–204.16244652 10.1038/nm1313
130. Bonadio J Gene therapy for tissue repair and regeneration Adv Drug Deliv Rev 1998 33 53 69 10.1016/S0169-409X(98)00020-9 10837653
Bonadio J, et al. Gene therapy for tissue repair and regeneration. Adv Drug Deliv Rev. 1998;33:53–69.10837653 10.1016/S0169-409X(98)00020-9
131. Yan R An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair Cell Stem Cell 2023 30 96 111 10.1016/j.stem.2022.11.012 36516837
Yan R, Cigliola V, Oonk KA, Petrover Z, DeLuca S, Wolfson DW, et al. An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair. Cell Stem Cell. 2023;30:96–111.36516837 10.1016/j.stem.2022.11.012
132. Ikada Y Challenges in tissue engineering J R Soc Interface 2006 3 589 601 10.1098/rsif.2006.0124 16971328
Ikada Y. Challenges in tissue engineering. J R Soc Interface. 2006;3:589–601.16971328 10.1098/rsif.2006.0124
133. Almeida GHD Uterine tissue engineering: where we stand and the challenges ahead Tissue Eng Part B Rev 2022 28 861 90 10.1089/ten.teb.2021.0062 34476997
Almeida GHD, et al. Uterine tissue engineering: where we stand and the challenges ahead. Tissue Eng Part B Rev. 2022;28:861–90.34476997 10.1089/ten.teb.2021.0062
134. Wang S Advances in translational 3D printing for cartilage, bone, and osteochondral tissue engineering Small 2022 18 e2201869 10.1002/smll.202201869 35713246
Wang S, et al. Advances in translational 3D printing for cartilage, bone, and osteochondral tissue engineering. Small. 2022;18:e2201869.35713246 10.1002/smll.202201869
135. Yu L Gradient degradable nerve guidance conduit with multilayer structure prepared by electrospinning Mater Lett 2020 276 128238 10.1016/j.matlet.2020.128238
Yu L, et al. Gradient degradable nerve guidance conduit with multilayer structure prepared by electrospinning. Mater Lett. 2020;276:128238.10.1016/j.matlet.2020.128238
136. Cai J, Wang J, Sun C, Dai J, Zhang C. Biomaterials with stiffness gradient for interface tissue engineering. Biomed Mater 2022;17.
137. Wang Y Collagen-based biomaterials for tissue engineering ACS Biomater Sci Eng 2023 9 1132 50 10.1021/acsbiomaterials.2c00730 36800415
Wang Y, et al. Collagen-based biomaterials for tissue engineering. ACS Biomater Sci Eng. 2023;9:1132–50.36800415 10.1021/acsbiomaterials.2c00730
138. Forbes SJ Preparing the ground for tissue regeneration: from mechanism to therapy Nat Med 2014 20 857 69 10.1038/nm.3653 25100531
Forbes SJ, et al. Preparing the ground for tissue regeneration: from mechanism to therapy. Nat Med. 2014;20:857–69.25100531 10.1038/nm.3653
139. Zhuang Y Biomaterial-based delivery of nucleic acids for tissue regeneration Adv Drug Deliv Rev 2021 176 113885 10.1016/j.addr.2021.113885 34324886
Zhuang Y, et al. Biomaterial-based delivery of nucleic acids for tissue regeneration. Adv Drug Deliv Rev. 2021;176:113885.34324886 10.1016/j.addr.2021.113885
140. Kwon SG Recent advances in stem cell therapeutics and tissue engineering strategies Biomater Res 2018 22 1 8 10.1186/s40824-018-0148-4 29308274
Kwon SG, et al. Recent advances in stem cell therapeutics and tissue engineering strategies. Biomater Res. 2018;22:1–8.29308274 10.1186/s40824-018-0148-4
141. Wang Y Micropattern-controlled cell density and its effect on gene transfection of mesenchymal stem cells Adv Mater Interfaces 2022 9 2101978 10.1002/admi.202101978
Wang Y, et al. Micropattern-controlled cell density and its effect on gene transfection of mesenchymal stem cells. Adv Mater Interfaces. 2022;9:2101978.10.1002/admi.202101978
142. Wang Y Regulation of gene transfection by cell size, shape and elongation on micropatterned surfaces J Mater Chem B 2021 9 4329 39 10.1039/D1TB00815C 34013946
Wang Y, et al. Regulation of gene transfection by cell size, shape and elongation on micropatterned surfaces. J Mater Chem B. 2021;9:4329–39.34013946 10.1039/D1TB00815C
143. Wang Y The varied influences of cell adhesion and spreading on gene transfection of mesenchymal stem cells on a micropatterned substrate Acta Biomater 2021 125 100 11 10.1016/j.actbio.2021.01.042 33524558
Wang Y, et al. The varied influences of cell adhesion and spreading on gene transfection of mesenchymal stem cells on a micropatterned substrate. Acta Biomater. 2021;125:100–11.33524558 10.1016/j.actbio.2021.01.042
144. Zhang W A PDA-functionalized 3D lung scaffold bioplatform to construct complicated breast tumor microenvironment for anticancer drug screening and immunotherapy Adv Sci 2023 10 e2302855 10.1002/advs.202302855
Zhang W, et al. A PDA-functionalized 3D lung scaffold bioplatform to construct complicated breast tumor microenvironment for anticancer drug screening and immunotherapy. Adv Sci. 2023;10:e2302855.10.1002/advs.202302855
145. Dalton CJ Lemmon CA Fibronectin: molecular structure, fibrillar structure and mechanochemical signaling Cells 2021 10 2443 10.3390/cells10092443 34572092
Dalton CJ, Lemmon CA. Fibronectin: molecular structure, fibrillar structure and mechanochemical signaling. Cells. 2021;10:2443.34572092 10.3390/cells10092443
146. Singh P Assembly of fibronectin extracellular matrix Annu Rev Cell Dev Bi 2010 26 397 419 10.1146/annurev-cellbio-100109-104020
Singh P, et al. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Bi. 2010;26:397–419.10.1146/annurev-cellbio-100109-104020
147. Campbell ID Humphries MJ Integrin structure, activation, and interactions Cold Spring Harb Perspect Biol 2011 3 a004994 10.1101/cshperspect.a004994 21421922
Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3:a004994.21421922 10.1101/cshperspect.a004994
148. Koivisto L Integrin αvβ6: structure, function and role in health and disease Int J Biochem Cell Biol 2018 99 186 96 10.1016/j.biocel.2018.04.013 29678785
Koivisto L, et al. Integrin αvβ6: structure, function and role in health and disease. Int J Biochem Cell Biol. 2018;99:186–96.29678785 10.1016/j.biocel.2018.04.013
149. Wang Y Regulation of micropatterned curvature-dependent FA heterogeneity on cytoskeleton tension and nuclear DNA synthesis of malignant breast cancer cells J Mater Chem B 2023 11 99 108 10.1039/D2TB01774A
Wang Y, et al. Regulation of micropatterned curvature-dependent FA heterogeneity on cytoskeleton tension and nuclear DNA synthesis of malignant breast cancer cells. J Mater Chem B. 2023;11:99–108.10.1039/D2TB01774A
150. Wang Y Cellular nanomechanics derived from pattern-dependent focal adhesion and cytoskeleton to balance gene transfection of malignant osteosarcoma J Nanobiotechnol 2022 20 499 10.1186/s12951-022-01713-1
Wang Y, et al. Cellular nanomechanics derived from pattern-dependent focal adhesion and cytoskeleton to balance gene transfection of malignant osteosarcoma. J Nanobiotechnol. 2022;20:499.10.1186/s12951-022-01713-1
151. Sun Z Integrin activation by talin, kindlin and mechanical forces Nat Cell Biol 2019 21 25 31 10.1038/s41556-018-0234-9 30602766
Sun Z, et al. Integrin activation by talin, kindlin and mechanical forces. Nat Cell Biol. 2019;21:25–31.30602766 10.1038/s41556-018-0234-9
152. Zhao Y Talin–1 interaction network in cellular mechanotransduction Int J Mol Med 2022 49 60 10.3892/ijmm.2022.5116 35266014
Zhao Y, et al. Talin–1 interaction network in cellular mechanotransduction. Int J Mol Med. 2022;49:60.35266014 10.3892/ijmm.2022.5116
153. Bays JL DeMali KA Vinculin in cell-cell and cell-matrix adhesions Cell Mol Life Sci 2017 74 2999 3009 10.1007/s00018-017-2511-3 28401269
Bays JL, DeMali KA. Vinculin in cell-cell and cell-matrix adhesions. Cell Mol Life Sci. 2017;74:2999–3009.28401269 10.1007/s00018-017-2511-3
154. Liu J Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities Signal Transduct Target Ther 2022 7 3 10.1038/s41392-021-00762-6 34980884
Liu J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3.34980884 10.1038/s41392-021-00762-6
155. Kobielak A α-catenin: at the junction of intercellular adhesion and actin dynamics Nat Rev Mol Cell Biol 2004 5 614 25 10.1038/nrm1433 15366705
Kobielak A, et al. α-catenin: at the junction of intercellular adhesion and actin dynamics. Nat Rev Mol Cell Biol. 2004;5:614–25.15366705 10.1038/nrm1433
156. Takata N Stem cells and genome editing: approaches to tissue regeneration and regenerative medicine J Hum Genet 2018 63 165 78 10.1038/s10038-017-0348-0 29192237
Takata N, et al. Stem cells and genome editing: approaches to tissue regeneration and regenerative medicine. J Hum Genet. 2018;63:165–78.29192237 10.1038/s10038-017-0348-0
157. Gaharwar AK Engineered biomaterials for in situ tissue regeneration Nat Rev Mater 2020 5 686 705 10.1038/s41578-020-0209-x
Gaharwar AK, et al. Engineered biomaterials for in situ tissue regeneration. Nat Rev Mater. 2020;5:686–705.10.1038/s41578-020-0209-x
158. Vo TN Strategies for controlled delivery of growth factors and cells for bone regeneration Adv Drug Deliv Rev 2012 64 1292 309 10.1016/j.addr.2012.01.016 22342771
Vo TN, et al. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012;64:1292–309.22342771 10.1016/j.addr.2012.01.016
159. Kofron MD Bone tissue engineering by gene delivery Adv Drug Deliv Rev 2006 58 555 76 10.1016/j.addr.2006.03.008 16790291
Kofron MD, et al. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev. 2006;58:555–76.16790291 10.1016/j.addr.2006.03.008
160. Jin L Current progress in gene delivery technology based on chemical methods and nano-carriers Theranostics 2014 4 240 10.7150/thno.6914 24505233
Jin L, et al. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014;4:240.24505233 10.7150/thno.6914
161. Kwon H Surgical and tissue engineering strategies for articular cartilage and meniscus repair Nat Rev Rheumatol 2019 15 550 70 10.1038/s41584-019-0255-1 31296933
Kwon H, et al. Surgical and tissue engineering strategies for articular cartilage and meniscus repair. Nat Rev Rheumatol. 2019;15:550–70.31296933 10.1038/s41584-019-0255-1
162. Cai Y Enhanced osteoarthritis therapy by nanoengineered mesenchymal stem cells using biomimetic CuS nanoparticles loaded with plasmid DNA encoding TGF-β1 Bioact Mater 2023 19 444 57 35574050
Cai Y, et al. Enhanced osteoarthritis therapy by nanoengineered mesenchymal stem cells using biomimetic CuS nanoparticles loaded with plasmid DNA encoding TGF-β1. Bioact Mater. 2023;19:444–57.35574050
163. Bonato A Engineering inflammation-resistant cartilage: bridging gene therapy and tissue engineering Adv Healthc Mater 2023 12 e2202271 10.1002/adhm.202202271 36841937
Bonato A, et al. Engineering inflammation-resistant cartilage: bridging gene therapy and tissue engineering. Adv Healthc Mater. 2023;12:e2202271.36841937 10.1002/adhm.202202271
164. Rosenholm JM Mesoporous silica nanoparticles in tissue engineering–a perspective Nanomedicine 2016 11 391 402 10.2217/nnm.15.212 26784861
Rosenholm JM, et al. Mesoporous silica nanoparticles in tissue engineering–a perspective. Nanomedicine. 2016;11:391–402.26784861 10.2217/nnm.15.212
165. Wang J Mesoporous silica nanoparticles carrying microRNA-124 to target P2Y(12) facilitates cerebral angiogenesis in lacunar cerebral infarction through stem cell factor/c-kit signaling pathway J Biomed Nanotechnol 2022 18 218 24 10.1166/jbn.2022.3240 35180915
Wang J, et al. Mesoporous silica nanoparticles carrying microRNA-124 to target P2Y(12) facilitates cerebral angiogenesis in lacunar cerebral infarction through stem cell factor/c-kit signaling pathway. J Biomed Nanotechnol. 2022;18:218–24.35180915 10.1166/jbn.2022.3240
166. Hu N Hypoxia-pretreated ADSC-derived exosome-embedded hydrogels promote angiogenesis and accelerate diabetic wound healing Acta Biomater 2023 157 175 86 10.1016/j.actbio.2022.11.057 36503078
Hu N, et al. Hypoxia-pretreated ADSC-derived exosome-embedded hydrogels promote angiogenesis and accelerate diabetic wound healing. Acta Biomater. 2023;157:175–86.36503078 10.1016/j.actbio.2022.11.057
167. Grinsell D Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies Biomed Res Int 2014 2014 698256 10.1155/2014/698256 25276813
Grinsell D, et al. Peripheral nerve reconstruction after injury: a review of clinical and experimental therapies. Biomed Res Int. 2014;2014:698256.25276813 10.1155/2014/698256
168. Ma Y Exosomes released from neural progenitor cells and induced neural progenitor cells regulate neurogenesis through miR-21a Cell Commun Signal 2019 17 96 10.1186/s12964-019-0418-3 31419975
Ma Y, et al. Exosomes released from neural progenitor cells and induced neural progenitor cells regulate neurogenesis through miR-21a. Cell Commun Signal. 2019;17:96.31419975 10.1186/s12964-019-0418-3
169. Cao L Neural progenitor cell-derived nanovesicles promote hair follicle growth via miR-100 J Nanobiotechnol 2021 19 20 10.1186/s12951-020-00757-5
Cao L, et al. Neural progenitor cell-derived nanovesicles promote hair follicle growth via miR-100. J Nanobiotechnol. 2021;19:20.10.1186/s12951-020-00757-5
170. Majidinia M The roles of signaling pathways in bone repair and regeneration J Cell Physiol 2018 233 2937 48 10.1002/jcp.26042 28590066
Majidinia M, et al. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018;233:2937–48.28590066 10.1002/jcp.26042
171. Yudoh K, Sugishita Y, Suzuki-Takahashi Y. Bone development and regeneration 2.0. Int J Mol Sci. 2023;24:8761.
172. Lee J Current advances in immunomodulatory biomaterials for bone regeneration Adv Healthc Mater 2019 8 e1801106 10.1002/adhm.201801106 30328293
Lee J, et al. Current advances in immunomodulatory biomaterials for bone regeneration. Adv Healthc Mater. 2019;8:e1801106.30328293 10.1002/adhm.201801106
173. Elgali I Guided bone regeneration: materials and biological mechanisms revisited Eur J Oral Sci 2017 125 315 37 10.1111/eos.12364 28833567
Elgali I, et al. Guided bone regeneration: materials and biological mechanisms revisited. Eur J Oral Sci. 2017;125:315–37.28833567 10.1111/eos.12364
174. Este MD, Eglin D, Alini M, Kyllonen L. Bone regeneration with biomaterials and active molecules delivery. Curr Pharm Biotechnol. 2015;16:582–605.
175. Moriarty N A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells Cell Stem Cell 2022 29 434 48 10.1016/j.stem.2022.01.013 35180398
Moriarty N, et al. A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell. 2022;29:434–48.35180398 10.1016/j.stem.2022.01.013
176. Winn SR Gene therapy approaches for modulating bone regeneration Adv Drug Deliv Rev 2000 42 121 38 10.1016/S0169-409X(00)00057-0 10942818
Winn SR, et al. Gene therapy approaches for modulating bone regeneration. Adv Drug Deliv Rev. 2000;42:121–38.10942818 10.1016/S0169-409X(00)00057-0
177. Deckers R Image-guided, noninvasive, spatiotemporal control of gene expression PNAS 2009 106 1175 80 10.1073/pnas.0806936106 19164593
Deckers R, et al. Image-guided, noninvasive, spatiotemporal control of gene expression. PNAS. 2009;106:1175–80.19164593 10.1073/pnas.0806936106
178. Collon K Musculoskeletal tissue engineering: Regional gene therapy for bone repair Biomaterials 2021 275 120901 10.1016/j.biomaterials.2021.120901 34091300
Collon K, et al. Musculoskeletal tissue engineering: Regional gene therapy for bone repair. Biomaterials. 2021;275:120901.34091300 10.1016/j.biomaterials.2021.120901
179. Bessa PC Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery) J Tissue Eng Regen Med 2008 2 81 96 10.1002/term.74 18383454
Bessa PC, et al. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008;2:81–96.18383454 10.1002/term.74
180. Santos J Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration Curr Gene Ther 2011 11 46 57 10.2174/156652311794520102 21182464
Santos J, et al. Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration. Curr Gene Ther. 2011;11:46–57.21182464 10.2174/156652311794520102
181. Alsaggar M Physical methods for gene transfer Adv Genet 2015 89 1 24 10.1016/bs.adgen.2014.10.001 25620006
Alsaggar M, et al. Physical methods for gene transfer. Adv Genet. 2015;89:1–24.25620006 10.1016/bs.adgen.2014.10.001
182. Curtin CM Combinatorial gene therapy accelerates bone regeneration: non-viral dual delivery of VEGF and BMP2 in a collagen‐nanohydroxyapatite scaffold Adv Healthc Mater 2015 4 223 7 10.1002/adhm.201400397 25125073
Curtin CM, et al. Combinatorial gene therapy accelerates bone regeneration: non-viral dual delivery of VEGF and BMP2 in a collagen‐nanohydroxyapatite scaffold. Adv Healthc Mater. 2015;4:223–7.25125073 10.1002/adhm.201400397
183. Liu S Non-coding-RNA-activated core/chitosan shell nanounits coated with polyetheretherketone for promoting bone regeneration and osseointegration via osteoimmunology ACS Appl Mater Interfaces 2023 15 12653 68 10.1021/acsami.2c19186 36868875
Liu S, et al. Non-coding-RNA-activated core/chitosan shell nanounits coated with polyetheretherketone for promoting bone regeneration and osseointegration via osteoimmunology. ACS Appl Mater Interfaces. 2023;15:12653–68.36868875 10.1021/acsami.2c19186
184. Nguyen NTK, Chang YH, Truong VA, Hsu MN, Pham NN, Chang CW, et al. CRISPR activation of long non-coding RNA DANCR promotes bone regeneration. Biomaterials. 2021;275:120965.
185. Hao L Bone targeting miR-26a loaded exosome-mimetics for bone regeneration therapy by activating wnt signaling pathway Chem Eng J 2023 471 144594 10.1016/j.cej.2023.144594
Hao L, et al. Bone targeting miR-26a loaded exosome-mimetics for bone regeneration therapy by activating wnt signaling pathway. Chem Eng J. 2023;471:144594.10.1016/j.cej.2023.144594
186. Steinert AF Concepts in gene therapy for cartilage repair Injury 2008 39 97 113 10.1016/j.injury.2008.01.034
Steinert AF, et al. Concepts in gene therapy for cartilage repair. Injury. 2008;39:97–113.10.1016/j.injury.2008.01.034
187. Guo X Regeneration of articular cartilage defects: therapeutic strategies and perspectives J Tissue Eng 2023 14 20417314231164765 10.1177/20417314231164765 37025158
Guo X, et al. Regeneration of articular cartilage defects: therapeutic strategies and perspectives. J Tissue Eng. 2023;14:20417314231164765.37025158 10.1177/20417314231164765
188. Lee HP Mechanical confinement regulates cartilage matrix formation by chondrocytes Nat Mater 2017 16 1243 51 10.1038/nmat4993 28967913
Lee HP, et al. Mechanical confinement regulates cartilage matrix formation by chondrocytes. Nat Mater. 2017;16:1243–51.28967913 10.1038/nmat4993
189. Huo Y In vivo stable allogenic cartilage regeneration in a goat model based on immunoisolation strategy using electrospun semipermeable membranes Adv Healthc Mater 2023 12 2203084 10.1002/adhm.202203084
Huo Y, et al. In vivo stable allogenic cartilage regeneration in a goat model based on immunoisolation strategy using electrospun semipermeable membranes. Adv Healthc Mater. 2023;12:2203084.10.1002/adhm.202203084
190. Yang R Recent advances in polymeric biomaterials-based gene delivery for cartilage repair Bioact Mater 2020 5 990 1003 32671293
Yang R, et al. Recent advances in polymeric biomaterials-based gene delivery for cartilage repair. Bioact Mater. 2020;5:990–1003.32671293
191. Gonzalez-Fernandez T Pore-forming bioinks to enable spatio-temporally defined gene delivery in bioprinted tissues J Control Release 2019 301 13 27 10.1016/j.jconrel.2019.03.006 30853527
Gonzalez-Fernandez T, et al. Pore-forming bioinks to enable spatio-temporally defined gene delivery in bioprinted tissues. J Control Release. 2019;301:13–27.30853527 10.1016/j.jconrel.2019.03.006
192. Liu Q Inorganic nanoparticles applied as functional therapeutics Adv Funct Mater 2021 31 2008171 10.1002/adfm.202008171
Liu Q, et al. Inorganic nanoparticles applied as functional therapeutics. Adv Funct Mater. 2021;31:2008171.10.1002/adfm.202008171
193. Saraf A Gene delivery strategies for cartilage tissue engineering Adv Drug Deliv Rev 2006 58 592 603 10.1016/j.addr.2006.03.005 16766079
Saraf A, et al. Gene delivery strategies for cartilage tissue engineering. Adv Drug Deliv Rev. 2006;58:592–603.16766079 10.1016/j.addr.2006.03.005
194. Madry H Thermosensitive hydrogel based on PEO–PPO–PEO poloxamers for a controlled in situ release of recombinant adeno-associated viral vectors for effective gene therapy of cartilage defects Adv Mater 2020 32 1906508 10.1002/adma.201906508
Madry H, et al. Thermosensitive hydrogel based on PEO–PPO–PEO poloxamers for a controlled in situ release of recombinant adeno-associated viral vectors for effective gene therapy of cartilage defects. Adv Mater. 2020;32:1906508.10.1002/adma.201906508
195. Dong Y Spatiotemporal regulation of endogenous MSCs using a functional injectable hydrogel system for cartilage regeneration NPG Asia Mater 2021 13 71 10.1038/s41427-021-00339-3
Dong Y, et al. Spatiotemporal regulation of endogenous MSCs using a functional injectable hydrogel system for cartilage regeneration. NPG Asia Mater. 2021;13:71.10.1038/s41427-021-00339-3
196. Li M The immune microenvironment in cartilage injury and repair Acta Biomater 2022 140 23 42 10.1016/j.actbio.2021.12.006 34896634
Li M, et al. The immune microenvironment in cartilage injury and repair. Acta Biomater. 2022;140:23–42.34896634 10.1016/j.actbio.2021.12.006
197. Liu X Injectable catalyst-free click organic-inorganic nanohybrid (click-ON) cement for minimally invasive in vivo bone repair Biomaterials 2021 276 121014 10.1016/j.biomaterials.2021.121014 34280821
Liu X, et al. Injectable catalyst-free click organic-inorganic nanohybrid (click-ON) cement for minimally invasive in vivo bone repair. Biomaterials. 2021;276:121014.34280821 10.1016/j.biomaterials.2021.121014
198. Kim H-S Therapeutic tissue regenerative nanohybrids self-assembled from bioactive inorganic core/chitosan shell nanounits Biomaterials 2021 274 120857 10.1016/j.biomaterials.2021.120857 33965799
Kim HS, Lee JH, Mandakhbayar N, Jin GZ, Kim SJ, Yoon JY, et al. Therapeutic tissue regenerative nanohybrids self-assembled from bioactive inorganic core/chitosan shell nanounits. Biomaterials. 2021;274:120857.33965799 10.1016/j.biomaterials.2021.120857
199. Hayes AJ Glycosaminoglycan and proteoglycan biotherapeutics in articular cartilage protection and repair strategies: novel approaches to visco-supplementation in orthobiologics Adv Ther 2019 2 1900034 10.1002/adtp.201900034
Hayes AJ, et al. Glycosaminoglycan and proteoglycan biotherapeutics in articular cartilage protection and repair strategies: novel approaches to visco-supplementation in orthobiologics. Adv Ther. 2019;2:1900034.10.1002/adtp.201900034
200. Intini C An innovative mir-activated scaffold for the delivery of a miR-221 inhibitor to enhance cartilage defect repair Adv Ther 2023 6 2200329 10.1002/adtp.202200329
Intini C, et al. An innovative mir-activated scaffold for the delivery of a miR-221 inhibitor to enhance cartilage defect repair. Adv Ther. 2023;6:2200329.10.1002/adtp.202200329
201. Zhao RL, Zhang XM, Jia LN, Song W, Sun YL, Meng XY, Peng XX. p NNS-conjugated chitosan mediated IGF-1 and miR-140 overexpression in articular chondrocytes improves cartilage repair. Biomed Res Int. 2019;2019:2761241.
202. Zhao R Interleukin-1 receptor antagonist protein (IL-1Ra) and miR-140 overexpression via pNNS-conjugated chitosan-mediated gene transfer enhances the repair of full-thickness cartilage defects in a rabbit model Bone Joint Res 2019 8 165 78 10.1302/2046-3758.83.BJR-2018-0222.R1 30997042
Zhao R, et al. Interleukin-1 receptor antagonist protein (IL-1Ra) and miR-140 overexpression via pNNS-conjugated chitosan-mediated gene transfer enhances the repair of full-thickness cartilage defects in a rabbit model. Bone Joint Res. 2019;8:165–78.30997042 10.1302/2046-3758.83.BJR-2018-0222.R1
203. Huang J Advances in the study of exosomes as drug delivery systems for bone-related diseases Pharmaceutics 2023 15 220 10.3390/pharmaceutics15010220 36678850
Huang J, et al. Advances in the study of exosomes as drug delivery systems for bone-related diseases. Pharmaceutics. 2023;15:220.36678850 10.3390/pharmaceutics15010220
204. Mao GP Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A Stem Cell Res Ther 2018 9 247 10.1186/s13287-018-1004-0 30257711
Mao GP, et al. Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A. Stem Cell Res Ther. 2018;9:247.30257711 10.1186/s13287-018-1004-0
205. Xu HG, Xu B. BMSC-derived exosomes ameliorate osteoarthritis by inhibiting pyroptosis of cartilage via delivering miR-326 targeting HDAC3 and STAT1//NF-kappa B p65 to chondrocytes. Mediators Inflamm. 2021;2021:9972805.
206. Zhu W Advances in biomaterial-mediated gene therapy for articular cartilage repair Bioengineering 2022 9 502 10.3390/bioengineering9100502 36290470
Zhu W, et al. Advances in biomaterial-mediated gene therapy for articular cartilage repair. Bioengineering. 2022;9:502.36290470 10.3390/bioengineering9100502
207. Yang J Cell-laden hydrogels for osteochondral and cartilage tissue engineering Acta Biomater 2017 57 1 25 10.1016/j.actbio.2017.01.036 28088667
Yang J, et al. Cell-laden hydrogels for osteochondral and cartilage tissue engineering. Acta Biomater. 2017;57:1–25.28088667 10.1016/j.actbio.2017.01.036
208. Deng C et al. Application of chitosan-based biomaterials for blood vessel regeneration. Macromol Symp. 2010, 297: 138–146.
209. Chen Y In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles Adv Mater 2013 25 3144 76 10.1002/adma.201205292 23681931
Chen Y, et al. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater. 2013;25:3144–76.23681931 10.1002/adma.201205292
210. Paul A Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair ACS Nano 2014 8 8050 62 10.1021/nn5020787 24988275
Paul A, et al. Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano. 2014;8:8050–62.24988275 10.1021/nn5020787
211. Zheng SS Inhibition of neointimal hyperplasia in balloon-induced vascular injuries in a rat model by miR-22 loading Laponite hydrogels Biomater Adv 2022 142 213140 10.1016/j.bioadv.2022.213140 36228507
Zheng SS, et al. Inhibition of neointimal hyperplasia in balloon-induced vascular injuries in a rat model by miR-22 loading Laponite hydrogels. Biomater Adv. 2022;142:213140.36228507 10.1016/j.bioadv.2022.213140
212. Theoharis S Gene delivery to vascular endothelium using chemical vectors: implications for cardiovascular gene therapy Expert Opin Biol Ther 2007 7 627 43 10.1517/14712598.7.5.627 17477801
Theoharis S, et al. Gene delivery to vascular endothelium using chemical vectors: implications for cardiovascular gene therapy. Expert Opin Biol Ther. 2007;7:627–43.17477801 10.1517/14712598.7.5.627
213. Kagaya H Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions Gene Ther 2012 19 61 9 10.1038/gt.2011.74 21654819
Kagaya H, et al. Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions. Gene Ther. 2012;19:61–9.21654819 10.1038/gt.2011.74
214. Zhou F Nanofiber-mediated microRNA-126 delivery to vascular endothelial cells for blood vessel regeneration Acta Biomater 2016 43 303 13 10.1016/j.actbio.2016.07.048 27477849
Zhou F, et al. Nanofiber-mediated microRNA-126 delivery to vascular endothelial cells for blood vessel regeneration. Acta Biomater. 2016;43:303–13.27477849 10.1016/j.actbio.2016.07.048
215. Peng B MicroRNA delivery for regenerative medicine Adv Drug Deliv Rev 2015 88 108 22 10.1016/j.addr.2015.05.014 26024978
Peng B, et al. MicroRNA delivery for regenerative medicine. Adv Drug Deliv Rev. 2015;88:108–22.26024978 10.1016/j.addr.2015.05.014
216. Feghhi M Effect of multi-functional polyhydroxylated polyhedral oligomeric silsesquioxane (POSS) nanoparticles on the angiogenesis and exosome biogenesis in human umbilical vein endothelial cells (HUVECs) Mater Des 2021 197 109227 10.1016/j.matdes.2020.109227
Feghhi M, et al. Effect of multi-functional polyhydroxylated polyhedral oligomeric silsesquioxane (POSS) nanoparticles on the angiogenesis and exosome biogenesis in human umbilical vein endothelial cells (HUVECs). Mater Des. 2021;197:109227.10.1016/j.matdes.2020.109227
217. Dang JM Natural polymers for gene delivery and tissue engineering Adv Drug Deliv Rev 2006 58 487 99 10.1016/j.addr.2006.03.001 16762443
Dang JM, et al. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev. 2006;58:487–99.16762443 10.1016/j.addr.2006.03.001
218. Cojocaru E Electrospun-fibrous-architecture-mediated non-viral gene therapy drug delivery in regenerative medicine Polymers 2022 14 2647 10.3390/polym14132647 35808692
Cojocaru E, et al. Electrospun-fibrous-architecture-mediated non-viral gene therapy drug delivery in regenerative medicine. Polymers. 2022;14:2647.35808692 10.3390/polym14132647
219. Al-Dosari MS Nonviral gene delivery: principle, limitations, and recent progress AAPS J 2009 11 671 81 10.1208/s12248-009-9143-y 19834816
Al-Dosari MS, et al. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009;11:671–81.19834816 10.1208/s12248-009-9143-y
220. Carballo-Pedrares N Hydrogel-based localized nonviral gene delivery in regenerative medicine approaches—An overview Pharmaceutics 2020 12 752 10.3390/pharmaceutics12080752 32785171
Carballo-Pedrares N, et al. Hydrogel-based localized nonviral gene delivery in regenerative medicine approaches—An overview. Pharmaceutics. 2020;12:752.32785171 10.3390/pharmaceutics12080752
221. Hu H miR-23a-3p-abundant small extracellular vesicles released from Gelma/nanoclay hydrogel for cartilage regeneration J Extracell Vesicles 2020 9 1778883 10.1080/20013078.2020.1778883 32939233
Hu H, et al. miR-23a-3p-abundant small extracellular vesicles released from Gelma/nanoclay hydrogel for cartilage regeneration. J Extracell Vesicles. 2020;9:1778883.32939233 10.1080/20013078.2020.1778883
222. Campbell WW Evaluation and management of peripheral nerve injury Neurophysiol Clin 2008 119 1951 65 10.1016/j.clinph.2008.03.018
Campbell WW. Evaluation and management of peripheral nerve injury. Neurophysiol Clin. 2008;119:1951–65.10.1016/j.clinph.2008.03.018
223. Scheib J Advances in peripheral nerve regeneration Nat Rev Neurol 2013 9 668 76 10.1038/nrneurol.2013.227 24217518
Scheib J, et al. Advances in peripheral nerve regeneration. Nat Rev Neurol. 2013;9:668–76.24217518 10.1038/nrneurol.2013.227
224. Mason RJ Gene therapy for the peripheral nervous system: a strategy to repair the injured nerve? Curr Gene Ther 2011 11 75 89 10.2174/156652311794940764 21291360
Mason RJ. Gene therapy for the peripheral nervous system: a strategy to repair the injured nerve? Curr Gene Ther. 2011;11:75–89.21291360 10.2174/156652311794940764
225. Zhang N Localised non-viral delivery of nucleic acids for nerve regeneration in injured nervous systems Exp Neurol 2019 319 112820 10.1016/j.expneurol.2018.09.003 30195695
Zhang N, et al. Localised non-viral delivery of nucleic acids for nerve regeneration in injured nervous systems. Exp Neurol. 2019;319:112820.30195695 10.1016/j.expneurol.2018.09.003
226. Shi L Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord Gene Ther 2003 10 1179 88 10.1038/sj.gt.3301970 12833127
Shi L, et al. Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther. 2003;10:1179–88.12833127 10.1038/sj.gt.3301970
227. Jialin Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush Int J Nanomed 2017 12 4195 208 10.2147/IJN.S132190
Song J, Li X, Li Y, Che J, Li X, Zhao X, et al. Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush. Int J Nanomed. 2017;12:4195–208.10.2147/IJN.S132190
228. Mittnacht U Chitosan/siRNA nanoparticles biofunctionalize nerve implants and enable neurite outgrowth Nano Lett 2010 10 3933 9 10.1021/nl1016909 20795625
Mittnacht U, et al. Chitosan/siRNA nanoparticles biofunctionalize nerve implants and enable neurite outgrowth. Nano Lett. 2010;10:3933–9.20795625 10.1021/nl1016909
229. Li Z Silk fibroin nanofibrous scaffolds incorporated with microRNA-222 loaded chitosan nanoparticles for enhanced neuronal differentiation of neural stem cells Carbohyd Polym 2022 277 118791 10.1016/j.carbpol.2021.118791
Li Z, et al. Silk fibroin nanofibrous scaffolds incorporated with microRNA-222 loaded chitosan nanoparticles for enhanced neuronal differentiation of neural stem cells. Carbohyd Polym. 2022;277:118791.10.1016/j.carbpol.2021.118791
230. Uchida S In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle PLoS ONE 2013 8 e56220 10.1371/journal.pone.0056220 23418537
Uchida S, et al. In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS ONE. 2013;8:e56220.23418537 10.1371/journal.pone.0056220
231. Rong Y Engineered extracellular vesicles for delivery of siRNA promoting targeted repair of traumatic spinal cord injury Bioact Mater 2023 23 328 42 36474657
Rong Y, et al. Engineered extracellular vesicles for delivery of siRNA promoting targeted repair of traumatic spinal cord injury. Bioact Mater. 2023;23:328–42.36474657
232. Nguyen LH Three-dimensional aligned nanofibers-hydrogel scaffold for controlled non-viral drug/gene delivery to direct axon regeneration in spinal cord injury treatment Sci Rep 2017 7 42212 10.1038/srep42212 28169354
Nguyen LH, et al. Three-dimensional aligned nanofibers-hydrogel scaffold for controlled non-viral drug/gene delivery to direct axon regeneration in spinal cord injury treatment. Sci Rep. 2017;7:42212.28169354 10.1038/srep42212
233. Uchida S Treatment of spinal cord injury by an advanced cell transplantation technology using brain-derived neurotrophic factor-transfected mesenchymal stem cell spheroids Biomaterials 2016 109 1 11 10.1016/j.biomaterials.2016.09.007 27639527
Uchida S, et al. Treatment of spinal cord injury by an advanced cell transplantation technology using brain-derived neurotrophic factor-transfected mesenchymal stem cell spheroids. Biomaterials. 2016;109:1–11.27639527 10.1016/j.biomaterials.2016.09.007
234. Tawfik M Gene therapy with caspase-3 small interfering RNA-nanoparticles is neuroprotective after optic nerve damage Neural Regen Res 2021 16 2534 41 10.4103/1673-5374.313068 33907045
Tawfik M, et al. Gene therapy with caspase-3 small interfering RNA-nanoparticles is neuroprotective after optic nerve damage. Neural Regen Res. 2021;16:2534–41.33907045 10.4103/1673-5374.313068
235. Chang M-F Effective gene expression in the rat dorsal root ganglia with a non-viral vector delivered via spinal nerve injection Sci Rep 2016 6 35612 10.1038/srep35612 27748450
Chang MF, Hsieh JH, Chiang H, Kan HW, Huang CM, Chellis L, et al. Effective gene expression in the rat dorsal root ganglia with a non-viral vector delivered via spinal nerve injection. Sci Rep. 2016;6:35612.27748450 10.1038/srep35612
236. Zou L Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications Gene Ther 1999 6 994 1005 10.1038/sj.gt.3300936 10455401
Zou L, et al. Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications. Gene Ther. 1999;6:994–1005.10455401 10.1038/sj.gt.3300936
237. Kim YH, Lee K, Li S. Nucleic acids based polyelectrolyte complexes: their complexation mechanism, morphology, and stability. Chem Mater. 2021;33:7923–43.
238. Caplen NJ Nucleic acid transfer using cationic lipids Gene Target Protoc 2000 133 1 19
Caplen NJ. Nucleic acid transfer using cationic lipids. Gene Target Protoc. 2000;133:1–19.
239. Han Z Establishment of lipofection protocol for efficient miR-21 transfection into cortical neurons in vitro DNA Cell Biol 2015 34 703 9 10.1089/dna.2015.2800 26485116
Han Z, et al. Establishment of lipofection protocol for efficient miR-21 transfection into cortical neurons in vitro. DNA Cell Biol. 2015;34:703–9.26485116 10.1089/dna.2015.2800
240. Jiang XC Neural stem cells transfected with reactive oxygen species–responsive polyplexes for effective treatment of ischemic stroke Adv Mater 2019 31 1807591 10.1002/adma.201807591
Jiang XC, et al. Neural stem cells transfected with reactive oxygen species–responsive polyplexes for effective treatment of ischemic stroke. Adv Mater. 2019;31:1807591.10.1002/adma.201807591
241. Ogris M Tumor-targeted gene therapy: strategies for the preparation of ligand–polyethylene glycol–polyethylenimine/DNA complexes J Control Release 2003 91 173 81 10.1016/S0168-3659(03)00230-X 12932649
Ogris M, et al. Tumor-targeted gene therapy: strategies for the preparation of ligand–polyethylene glycol–polyethylenimine/DNA complexes. J Control Release. 2003;91:173–81.12932649 10.1016/S0168-3659(03)00230-X
242. Song J Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush Int J Nanomed 2017 12 4195 208 10.2147/IJN.S132190
Song J, et al. Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush. Int J Nanomed. 2017;12:4195–208.10.2147/IJN.S132190
243. Raviña M Hyaluronic acid/chitosan-g-poly (ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery Pharm Res 2010 27 2544 55 10.1007/s11095-010-0263-y 20857179
Raviña M, et al. Hyaluronic acid/chitosan-g-poly (ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery. Pharm Res. 2010;27:2544–55.20857179 10.1007/s11095-010-0263-y
244. Lu H Porous chitosan scaffolds with embedded hyaluronic acid/chitosan/plasmid-DNA nanoparticles encoding TGF-β1 induce DNA controlled release, transfected chondrocytes, and promoted cell proliferation PLoS ONE 2013 8 e69950 10.1371/journal.pone.0069950 23894564
Lu H, et al. Porous chitosan scaffolds with embedded hyaluronic acid/chitosan/plasmid-DNA nanoparticles encoding TGF-β1 induce DNA controlled release, transfected chondrocytes, and promoted cell proliferation. PLoS ONE. 2013;8:e69950.23894564 10.1371/journal.pone.0069950
245. Malmo J Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach PLoS ONE 2013 8 e54182 10.1371/journal.pone.0054182 23372682
Malmo J, et al. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach. PLoS ONE. 2013;8:e54182.23372682 10.1371/journal.pone.0054182
246. Højris I Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials Lancet 1999 354 1425 30 10.1016/S0140-6736(99)02245-X 10543669
Højris I, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet. 1999;354:1425–30.10543669 10.1016/S0140-6736(99)02245-X
247. Roma-Rodrigues C Gene therapy in cancer treatment: why go nano? Pharmaceutics 2020 12 233 10.3390/pharmaceutics12030233 32151052
Roma-Rodrigues C, et al. Gene therapy in cancer treatment: why go nano? Pharmaceutics. 2020;12:233.32151052 10.3390/pharmaceutics12030233
248. Witzigmann D Lipid nanoparticle technology for therapeutic gene regulation in the liver Adv Drug Deliver Rev 2020 159 344 63 10.1016/j.addr.2020.06.026
Witzigmann D, et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv Drug Deliver Rev. 2020;159:344–63.10.1016/j.addr.2020.06.026
249. Caplen N Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference Gene Ther 2004 11 1241 8 10.1038/sj.gt.3302324 15292914
Caplen N. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 2004;11:1241–8.15292914 10.1038/sj.gt.3302324
250. Luo Y 3D printing of hydrogel scaffolds for future application in photothermal therapy of breast cancer and tissue repair Acta Biomater 2019 92 37 47 10.1016/j.actbio.2019.05.039 31108260
Luo Y, et al. 3D printing of hydrogel scaffolds for future application in photothermal therapy of breast cancer and tissue repair. Acta Biomater. 2019;92:37–47.31108260 10.1016/j.actbio.2019.05.039
251. Suárez-González D Controlled nucleation of hydroxyapatite on alginate scaffolds for stem cell-based bone tissue engineering J Biomed Mater Res A 2010 95A 222 34 10.1002/jbm.a.32833
Suárez-González D, et al. Controlled nucleation of hydroxyapatite on alginate scaffolds for stem cell-based bone tissue engineering. J Biomed Mater Res A. 2010;95A:222–34.10.1002/jbm.a.32833
252. Yang P Functionalized mesoporous silica materials for controlled drug delivery Chem Soc Rev 2012 41 3679 98 10.1039/c2cs15308d 22441299
Yang P, et al. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev. 2012;41:3679–98.22441299 10.1039/c2cs15308d
253. Lin G Inorganic nanomaterial-mediated gene therapy in combination with other antitumor treatment modalities Adv Funct Mater 2021 31 2007096 10.1002/adfm.202007096 34366761
Lin G, et al. Inorganic nanomaterial-mediated gene therapy in combination with other antitumor treatment modalities. Adv Funct Mater. 2021;31:2007096.34366761 10.1002/adfm.202007096
254. Loh XJ Utilising inorganic nanocarriers for gene delivery Biomater Sci 2016 4 70 86 10.1039/C5BM00277J 26484365
Loh XJ, et al. Utilising inorganic nanocarriers for gene delivery. Biomater Sci. 2016;4:70–86.26484365 10.1039/C5BM00277J
255. Cristofolini T Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells Mat Sci Eng C 2020 109 110555 10.1016/j.msec.2019.110555
Cristofolini T, et al. Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells. Mat Sci Eng C. 2020;109:110555.10.1016/j.msec.2019.110555
256. Kara G Development of novel poly-l-lysine-modified sericin-coated superparamagnetic iron oxide nanoparticles as siRNA carrier Colloid Surf A 2021 630 127622 10.1016/j.colsurfa.2021.127622
Kara G, et al. Development of novel poly-l-lysine-modified sericin-coated superparamagnetic iron oxide nanoparticles as siRNA carrier. Colloid Surf A. 2021;630:127622.10.1016/j.colsurfa.2021.127622
257. Sokolova V Inorganic nanoparticles as carriers of nucleic acids into cells Angew Chem Int Ed Engl 2008 47 1382 95 10.1002/anie.200703039 18098258
Sokolova V, et al. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl. 2008;47:1382–95.18098258 10.1002/anie.200703039
258. Labala S Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles Int J Pharmaceut 2017 525 407 17 10.1016/j.ijpharm.2017.03.087
Labala S, et al. Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles. Int J Pharmaceut. 2017;525:407–17.10.1016/j.ijpharm.2017.03.087
259. Ball RL Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA Nano lett 2018 18 3814 22 10.1021/acs.nanolett.8b01101 29694050
Ball RL, et al. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano lett. 2018;18:3814–22.29694050 10.1021/acs.nanolett.8b01101
260. Tseng Y-C Lipid-based systemic delivery of siRNA Adv Drug Deliv Rev 2009 61 721 31 10.1016/j.addr.2009.03.003 19328215
Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 2009;61:721–31.19328215 10.1016/j.addr.2009.03.003
261. Subhan MA Advances in siRNA delivery strategies for the treatment of MDR cancer Life Sci 2021 274 119337 10.1016/j.lfs.2021.119337 33713664
Subhan MA, et al. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci. 2021;274:119337.33713664 10.1016/j.lfs.2021.119337
262. Chen G Development of fluorinated polyplex nanoemulsions for improved small interfering RNA delivery and cancer therapy Nano Res 2018 11 3746 61 10.1007/s12274-017-1946-z
Chen G, et al. Development of fluorinated polyplex nanoemulsions for improved small interfering RNA delivery and cancer therapy. Nano Res. 2018;11:3746–61.10.1007/s12274-017-1946-z
263. Bellavia D Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth Theranostics 2017 7 1333 10.7150/thno.17092 28435469
Bellavia D, et al. Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics. 2017;7:1333.28435469 10.7150/thno.17092
264. Zhou B Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF J Exp Clin Cancer Res 2023 42 48 10.1186/s13046-023-02620-5 36797769
Zhou B, Mo Z, Lai G, Chen X, Li R, Wu R, et al. Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-kB-IL-6 axis of tumor-associated macrophages. J Exp Clin Cancer Res. 2023;42:48.36797769 10.1186/s13046-023-02620-5
265. Ellipilli S Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression Nanomed-Nanotechnol 2023 50 102667 10.1016/j.nano.2023.102667
Ellipilli S, et al. Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression. Nanomed-Nanotechnol. 2023;50:102667.10.1016/j.nano.2023.102667
266. Dai S Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer Mol Ther 2008 16 782 90 10.1038/mt.2008.1 18362931
Dai S, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 2008;16:782–90.18362931 10.1038/mt.2008.1
267. Lee B-C Therapeutic features and updated clinical trials of mesenchymal stem cell (MSC)-derived exosomes J Clin Med 2021 10 711 10.3390/jcm10040711 33670202
Lee BC, Kang I, Yu KR. Therapeutic features and updated clinical trials of mesenchymal stem cell (MSC)-derived exosomes. J Clin Med. 2021;10:711.33670202 10.3390/jcm10040711
268. Raguraman R Tumor-targeted exosomes for delivery of anticancer drugs Cancer Lett 2023 558 216093 10.1016/j.canlet.2023.216093 36822543
Raguraman R, et al. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 2023;558:216093.36822543 10.1016/j.canlet.2023.216093
269. Kar R Exosome-based smart drug delivery tool for cancer theranostics Acs Biomater Sci Eng 2023 9 577 94 10.1021/acsbiomaterials.2c01329 36621949
Kar R, et al. Exosome-based smart drug delivery tool for cancer theranostics. Acs Biomater Sci Eng. 2023;9:577–94.36621949 10.1021/acsbiomaterials.2c01329
270. Wang T Exosome-based drug delivery systems in cancer therapy Chin Chem Lett 2023 34 107508 10.1016/j.cclet.2022.05.022
Wang T, et al. Exosome-based drug delivery systems in cancer therapy. Chin Chem Lett. 2023;34:107508.10.1016/j.cclet.2022.05.022
271. Copolovici DM Cell-penetrating peptides: design, synthesis, and applications ACS Nano 2014 8 1972 94 10.1021/nn4057269 24559246
Copolovici DM, et al. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8:1972–94.24559246 10.1021/nn4057269
272. Torchilin VP Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery Pept Sci 2008 90 604 10 10.1002/bip.20989
Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Pept Sci. 2008;90:604–10.10.1002/bip.20989
273. Deng Y, Song Y, Du Q, Wang CC, Li H, Sui Y, et al. Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12. Front Oncol. 2023;13:1175958.
274. Li C Nanocomposite multifunctional hydrogel for suppressing osteosarcoma recurrence and enhancing bone regeneration Chem Eng J 2022 435 134896 10.1016/j.cej.2022.134896
Li C, et al. Nanocomposite multifunctional hydrogel for suppressing osteosarcoma recurrence and enhancing bone regeneration. Chem Eng J. 2022;435:134896.10.1016/j.cej.2022.134896
275. Qin Y A novel long non-coding RNA lnc030 maintains breast cancer stem cell stemness by stabilizing SQLE mRNA and increasing cholesterol synthesis Adv Sci 2021 8 2002232 10.1002/advs.202002232
Qin Y, et al. A novel long non-coding RNA lnc030 maintains breast cancer stem cell stemness by stabilizing SQLE mRNA and increasing cholesterol synthesis. Adv Sci. 2021;8:2002232.10.1002/advs.202002232
276. Bai G Stimuli-responsive scaffold for breast cancer treatment combining accurate photothermal therapy and adipose tissue regeneration Adv Funct Mater 2019 29 1904401 10.1002/adfm.201904401
Bai G, et al. Stimuli-responsive scaffold for breast cancer treatment combining accurate photothermal therapy and adipose tissue regeneration. Adv Funct Mater. 2019;29:1904401.10.1002/adfm.201904401
277. Renneker R Cutler M Psychological problems of adjustment to cancer of the breast JAMA 1952 148 833 8 10.1001/jama.1952.02930100051011
Renneker R, Cutler M. Psychological problems of adjustment to cancer of the breast. JAMA. 1952;148:833–8.10.1001/jama.1952.02930100051011
278. Lovelace DL Long-term effects of breast cancer surgery, treatment, and survivor care J Midwifery Womens Health 2019 64 713 24 10.1111/jmwh.13012 31322834
Lovelace DL, et al. Long-term effects of breast cancer surgery, treatment, and survivor care. J Midwifery Womens Health. 2019;64:713–24.31322834 10.1111/jmwh.13012
279. Chhaya MP Sustained regeneration of high-volume adipose tissue for breast reconstruction using computer aided design and biomanufacturing Biomaterials 2015 52 551 60 10.1016/j.biomaterials.2015.01.025 25818460
Chhaya MP, et al. Sustained regeneration of high-volume adipose tissue for breast reconstruction using computer aided design and biomanufacturing. Biomaterials. 2015;52:551–60.25818460 10.1016/j.biomaterials.2015.01.025
280. Sun R Composite scaffolds of gelatin and Fe3O4 nanoparticles for magnetic hyperthermia-based breast cancer treatment and adipose tissue regeneration Adv Healthc Mater 2023 12 2202604 10.1002/adhm.202202604
Sun R, et al. Composite scaffolds of gelatin and Fe3O4 nanoparticles for magnetic hyperthermia-based breast cancer treatment and adipose tissue regeneration. Adv Healthc Mater. 2023;12:2202604.10.1002/adhm.202202604
281. Wang X Bifunctional scaffolds for the photothermal therapy of breast tumor cells and adipose tissue regeneration J Mater Chem B 2018 6 7728 36 10.1039/C8TB02325E 32254895
Wang X, et al. Bifunctional scaffolds for the photothermal therapy of breast tumor cells and adipose tissue regeneration. J Mater Chem B. 2018;6:7728–36.32254895 10.1039/C8TB02325E
282. Liao J Review of a new bone tumor therapy strategy based on bifunctional biomaterials Bone Res 2021 9 18 10.1038/s41413-021-00139-z 33727543
Liao J, et al. Review of a new bone tumor therapy strategy based on bifunctional biomaterials. Bone Res. 2021;9:18.33727543 10.1038/s41413-021-00139-z
283. Huang X Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma Colloid Surf B 2020 190 110891 10.1016/j.colsurfb.2020.110891
Huang X, et al. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma. Colloid Surf B. 2020;190:110891.10.1016/j.colsurfb.2020.110891
284. Wang H Integrative treatment of anti-tumor/bone repair by combination of MoS2 nanosheets with 3D printed bioactive borosilicate glass scaffolds Chem Eng J 2020 396 125081 10.1016/j.cej.2020.125081
Wang H, et al. Integrative treatment of anti-tumor/bone repair by combination of MoS2 nanosheets with 3D printed bioactive borosilicate glass scaffolds. Chem Eng J. 2020;396:125081.10.1016/j.cej.2020.125081
285. Maleki Dana P Chitosan applications in studying and managing osteosarcoma Int J Biol Macromol 2021 169 321 9 10.1016/j.ijbiomac.2020.12.058 33310094
Maleki Dana P, et al. Chitosan applications in studying and managing osteosarcoma. Int J Biol Macromol. 2021;169:321–9.33310094 10.1016/j.ijbiomac.2020.12.058
286. Ravanbakhsh M Mesoporous bioactive glasses for the combined application of osteosarcoma treatment and bone regeneration Mater Sci Eng C 2019 104 109994 10.1016/j.msec.2019.109994
Ravanbakhsh M, et al. Mesoporous bioactive glasses for the combined application of osteosarcoma treatment and bone regeneration. Mater Sci Eng C. 2019;104:109994.10.1016/j.msec.2019.109994
287. Li Z An update on the roles of circular RNAs in osteosarcoma Cell Prolif 2021 54 e12936 10.1111/cpr.12936 33103338
Li Z, et al. An update on the roles of circular RNAs in osteosarcoma. Cell Prolif. 2021;54:e12936.33103338 10.1111/cpr.12936
288. Zhou Y Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma Nat Commun 2020 11 6322 10.1038/s41467-020-20059-6 33303760
Zhou Y, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11:6322.33303760 10.1038/s41467-020-20059-6
289. He C Photosynthetic oxygen-self-generated 3D-printing microbial scaffold enhances osteosarcoma elimination and prompts bone regeneration Nano Today 2021 41 101297 10.1016/j.nantod.2021.101297
He C, et al. Photosynthetic oxygen-self-generated 3D-printing microbial scaffold enhances osteosarcoma elimination and prompts bone regeneration. Nano Today. 2021;41:101297.10.1016/j.nantod.2021.101297
290. Geng B Carbon dot/WS2 heterojunctions for NIR-II enhanced photothermal therapy of osteosarcoma and bone regeneration Chem Eng J 2020 383 123102 10.1016/j.cej.2019.123102
Geng B, et al. Carbon dot/WS2 heterojunctions for NIR-II enhanced photothermal therapy of osteosarcoma and bone regeneration. Chem Eng J. 2020;383:123102.10.1016/j.cej.2019.123102
291. Han J Controllable assembly/disassembly of polyphenol-DNA nanocomplex for cascade-responsive drug release in cancer cells Biomaterials 2021 273 120846 10.1016/j.biomaterials.2021.120846 33930736
Han J, et al. Controllable assembly/disassembly of polyphenol-DNA nanocomplex for cascade-responsive drug release in cancer cells. Biomaterials. 2021;273:120846.33930736 10.1016/j.biomaterials.2021.120846
292. Han J Responsive disassembly of nucleic acid nanocomplex in cells for precision medicine Nano Today 2021 39 101160 10.1016/j.nantod.2021.101160
Han J, et al. Responsive disassembly of nucleic acid nanocomplex in cells for precision medicine. Nano Today. 2021;39:101160.10.1016/j.nantod.2021.101160
293. Ding J Stealth and fully-laden drug carriers: self-assembled nanogels encapsulated with epigallocatechin gallate and siRNA for drug-resistant breast cancer therapy ACS Appl Mater Inter 2018 10 9938 48 10.1021/acsami.7b19577
Ding J, et al. Stealth and fully-laden drug carriers: self-assembled nanogels encapsulated with epigallocatechin gallate and siRNA for drug-resistant breast cancer therapy. ACS Appl Mater Inter. 2018;10:9938–48.10.1021/acsami.7b19577
294. Xiong L Magnetic core–shell silica nanoparticles with large radial mesopores for siRNA delivery Small 2016 12 4735 42 10.1002/smll.201600531 27199216
Xiong L, et al. Magnetic core–shell silica nanoparticles with large radial mesopores for siRNA delivery. Small. 2016;12:4735–42.27199216 10.1002/smll.201600531
295. Chen Z Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo Biomaterials 2016 81 125 34 10.1016/j.biomaterials.2015.11.022 26731576
Chen Z, et al. Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. Biomaterials. 2016;81:125–34.26731576 10.1016/j.biomaterials.2015.11.022
296. Chen J Assembly of bioactive nanoparticles via metal–phenolic complexation Adv Mater 2022 34 2108624 10.1002/adma.202108624
Chen J, et al. Assembly of bioactive nanoparticles via metal–phenolic complexation. Adv Mater. 2022;34:2108624.10.1002/adma.202108624
297. Kim C-J Engineering programmable DNA particles and capsules using catechol-functionalized DNA block copolymers Chem Mater 2022 34 7468 80 10.1021/acs.chemmater.2c01586
Kim C-J, et al. Engineering programmable DNA particles and capsules using catechol-functionalized DNA block copolymers. Chem Mater. 2022;34:7468–80.10.1021/acs.chemmater.2c01586
298. Wang Y Sustained gene delivery from inflammation-responsive anti-inflammatory hydrogels promotes extracellular matrix metabolism balance in degenerative nucleus pulposus Compos Part B-Eng 2022 236 109806 10.1016/j.compositesb.2022.109806
Wang Y, et al. Sustained gene delivery from inflammation-responsive anti-inflammatory hydrogels promotes extracellular matrix metabolism balance in degenerative nucleus pulposus. Compos Part B-Eng. 2022;236:109806.10.1016/j.compositesb.2022.109806
299. Eelen G Basic and therapeutic aspects of angiogenesis updated Circ Res 2020 127 310 29 10.1161/CIRCRESAHA.120.316851 32833569
Eelen G, et al. Basic and therapeutic aspects of angiogenesis updated. Circ Res. 2020;127:310–29.32833569 10.1161/CIRCRESAHA.120.316851
300. Majidinia M, et al. The roles of signaling pathways in bone repair and regeneration. J Cell Physiol. 2018, 233:2937–2948.
301. Pfister BJ Biomedical engineering strategies for peripheral nerve repair: surgical applications, state of the art, and future challenges Crit Rev Biomed Eng 2011 39 81 124 10.1615/CritRevBiomedEng.v39.i2.20 21488817
Pfister BJ, et al. Biomedical engineering strategies for peripheral nerve repair: surgical applications, state of the art, and future challenges. Crit Rev Biomed Eng. 2011;39:81–124.21488817 10.1615/CritRevBiomedEng.v39.i2.20
302. Yudoh K, Sugishita Y, Suzuki-Takahashi Y. Bone development and regeneration 2.0. Int J Mol Sci. 2023;24:8761.
303. Dhandapani RK Development of catechin, poly-l-lysine, and double-stranded RNA nanoparticles ACS Appl Bio Mater 2021 4 4310 8 10.1021/acsabm.1c00109 35006843
Dhandapani RK, et al. Development of catechin, poly-l-lysine, and double-stranded RNA nanoparticles. ACS Appl Bio Mater. 2021;4:4310–8.35006843 10.1021/acsabm.1c00109
